

RECOMBINANT NEWCASTLE DISEASE VIRUS AND PREPARATION METHOD, RECOMBINANT PLASMID, AND USE THEREFOR

Technical Field

5 **[0001]** The present application in general relates to the field of biotechnologies, in particular to a recombinant Newcastle disease virus and a preparation method therefor, a recombinant plasmid, and use thereof.

Background

10 **[0002]** Major means for treating cancers include surgeries, radiotherapies, chemotherapies, immunotherapies, monoclonal antibody therapies, and viral vaccines.

15 **[0003]** Malignant tumours are one of the major diseases endangering human's health. According to the data in 2015 Global Cancer Statistics, there were about 14.1 million new cancer cases and up to 8.2 million cancer deaths across the world in 2015. It is predicted that by 2025, the number of new cancer cases across the world every year will reach up to 24.49 million. For a long time, the methods adopted by people to treat cancers mainly include traditional surgical resections, radiotherapies, and chemotherapies. These methods can control the development of tumours to some extent, but showing limited efficacy for patients with advanced tumour spread, and at the same time, causing severe trauma to the normal cells of a human body. Therefore, there is an urgent need for a new method for treating a malignant tumour. An oncolytic virus therapy is a novel tumour treatment method by which a tumour is killed by selectively infecting tumour cells with viruses. As an important part of tumour immunity, it has a great advantage as compared with other tumour immunotherapies. The oncolytic virus therapy has undergone three stages of development, and has achieved great results. At present, the anti-tumour effect can be enhanced by carrying exogenous genes, among which T-vec carrying GM-CSF exhibits a good efficacy and was approved by the US FDA in 2015 for the local treatment of an unresectable melanoma that recurred for the first time. In December of the same year, T-vec was

20

25

further approved by the European Union, indicating a great development potential of oncolytic viruses.

[0004] In 1950s, it was found that Newcastle disease viruses (NDV) were capable of inhibiting the metastasis of gastric cancer. Therefore, NDV can be used as an emerging tumour biotherapeutic factor, and its application to tumour treatment has been studied deeper and deeper due to its high targeting property and the maturity of molecular biotechnologies. As a single negative-stranded RNA virus, NDV encodes six types of structural proteins (L, NP, P, HN, F, and M).

[0005] Compared with other oncolytic viruses, the Newcastle disease virus has a natural targeting property against tumour cells, and broad-spectrum anti-tumour properties, showing greater advantages in the anti-tumour aspect. However, how to improve its oncolytic effect and to ensure its safety is still a huge challenge for us to be confronted with.

Summary

[0006] An object of the present application is to provide a recombinant Newcastle disease virus and a preparation method therefor, a recombinant plasmid, and use thereof.

[0007] The present application provides a recombinant Newcastle disease virus obtained by replacing an F protein of a Newcastle disease virus Losata with an F protein of a Newcastle disease virus virulent strain.

[0008] Optionally, according to the recombinant Newcastle disease virus mentioned above, a coding DNA of an F protein of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1 at positions 7274-8935 from a 5'-terminus.

[0009] Optionally, according to the recombinant Newcastle disease virus mentioned above, the recombinant Newcastle disease virus is obtained by replacing an F gene in a genome of the Newcastle disease virus Losata with an F gene of the

Newcastle disease virus virulent strain. Preferably, a DNA corresponding to the F gene of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1 at the positions 7274-8935 from the 5'-terminus. More preferably, a DNA corresponding to a genome of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1.

5 **[0010]** Optionally, according to the recombinant Newcastle disease virus mentioned above, a DNA corresponding to a genome of the recombinant Newcastle disease virus further comprises an exogenous gene, which is selected from one or more of a group consisting of DR5, TRAIL, hIL2, P53, PD1, CD, and mIL12.

10 **[0011]** Preferably, the exogenous gene is DR5, TRAIL, hIL2, P53, PD1, CD, or mIL12.

[0012] Preferably, the exogenous gene is mIL12-hIL2, P53-hIL2, PD1-hIL2, or DR5-TRAIL.

15 **[0013]** Preferably, the DR5 is as set forth in SEQ ID NO: 2, the TRAIL is as set forth in SEQ ID NO: 3, the hIL2 is as set forth in SEQ ID NO: 4, the P53 is as set forth in SEQ ID NO: 5, the PD1 is as set forth in SEQ ID NO: 6, the CD is as set forth in SEQ ID NO: 7, and the mIL12 is as set forth in SEQ ID NO: 8.

[0014] Preferably, the exogenous gene is located between a P gene and an M gene of the recombinant Newcastle disease virus.

20 **[0015]** The present application further provides a recombinant plasmid obtained by replacing an F gene in a pBrLosata plasmid, wherein the F gene of the recombinant plasmid is as set forth in SEQ ID NO: 1 at positions 7274-8935 from a 5'-terminus.

[0016] Optionally, according to the recombinant plasmid mentioned above, the recombinant plasmid is a DNA molecule plasmid as set forth in SEQ ID NO: 1.

[0017] Optionally, according to the recombinant plasmid mentioned above, the recombinant plasmid further comprises an exogenous gene, which is selected from one or more of a group consisting of DR5, TRAIL, hIL2, P53, PD1, CD, and mIL12.

[0018] Preferably, the exogenous gene is DR5, TRAIL, hIL2, P53, PD1, CD, or mIL12.

[0019] Preferably, the exogenous gene is mIL12-hIL2, P53-hIL2, PD1-hIL2, or DR5-TRAIL.

[0020] Preferably, the DR5 is as set forth in SEQ ID NO: 2, the TRAIL is as set forth in SEQ ID NO: 3, the hIL2 is as set forth in SEQ ID NO: 4, the P53 is as set forth in SEQ ID NO: 5, the PD1 is as set forth in SEQ ID NO: 6, the CD is as set forth in SEQ ID NO: 7, and the mIL12 is as set forth in SEQ ID NO: 8.

[0021] Preferably, the exogenous gene is located between a P gene and an M gene of a genome of the recombinant Newcastle disease virus.

[0022] The present application further provides a preparation method for a recombinant Newcastle disease virus, comprising transfecting the recombinant plasmid defined above to a cell or cell line for culturing to obtain the recombinant Newcastle disease virus.

[0023] Optionally, according to the preparation method mentioned above, the recombinant plasmid and a helper plasmid are co-transfected to a cell or cell line for culturing. The cell is a mammalian cell. The helper plasmid is, for example, a pBL-N plasmid, a pBL-P plasmid, or a pBL-L plasmid.

[0024] The present application further provides use of the recombinant Newcastle disease virus mentioned above or the recombinant plasmid in preparation of a drug. The drug has the following function(s) of (a) and/or (b) and/or (c): (a) treating a tumour; (b) inhibiting tumour cell proliferation; and (c) killing tumour cells.

[0025] The present application further provides a drug, comprising the recombinant Newcastle disease virus mentioned above, and /or the recombinant plasmid mentioned above. The drug has the following function(s) of (a) and/or (b) and/or (c): (a) treating a tumour; (b) inhibiting tumour cell proliferation; and (c) killing tumour cells.

[0026] Optionally, the tumour is selected from one or more of a group consisting of a liver cancer, a breast cancer, a non-small cell lung cancer, a melanoma, a neuroblastoma, a lung cancer, a pancreatic cancer, a thyroid cancer, a kidney cancer, a glioma, a myosarcoma, an esophageal cancer, a uterine cancer, a breast cancer, and a colon cancer.

[0027] Optionally, the tumour cell is selected from one or more of a group consisting of a liver cancer cell, a breast cancer cell, a non-small cell lung cancer cell, a melanoma cell, a neuroblastoma cell, a lung cancer cell, a pancreatic cancer cell, a thyroid cancer cell, a kidney cancer cell, a glioma cell, a myosarcoma cell, an esophageal cancer cell, a uterine cancer cell, a breast cancer cell, and a colon cancer cell.

[0028] In the present application, virus strains having a stronger effect of promoting cell fusion are screened out; the structural protein genes of the strains are acquired; structural protein genes of Losata are replaced by means of a reverse genetic manipulation technique and a molecular cloning technique; and exogenous genes are further inserted to successfully construct and rescue recombinant chimeric viruses. The recombinant chimeric viruses are continuously passaged in chicken embryos for 10 generations. The results of a proliferation stability experiment have demonstrated that the recombinant Newcastle disease virus could proliferate continuously and stably in the chicken embryos, and the effects of the recombinant chimeric virus on killing tumour cells are systematically compared.

[0029] The recombinant chimeric virus according to the present application

has good safety and is capable of effectively inhibiting tumour cells, promoting tumour cell apoptosis, and effectively treating a tumour.

Brief Description of the Drawings

[0030] FIG. 1 shows the results of a virus strain screening test according to Example 1;

[0031] FIG. 2 shows the results of an exogenous gene expression position determination test according to Example 2;

[0032] FIG. 3A to FIG. 3E show the killing effects of recombinant chimeric viruses against tumour cells as detected in a cell fusion experiment according to Example 4;

[0033] FIG. 4 shows the killing effects of recombinant chimeric viruses against HepG-2 cells as detected by an MTT method according to Example 5;

[0034] FIG. 5 shows the killing effects of recombinant chimeric viruses against U251 cells as detected by the MTT method according to Example 5;

[0035] FIG. 6 shows the killing effects of recombinant chimeric viruses against MDA-MB-231 cells as detected by the MTT method according to Example 5;

[0036] FIG. 7 shows the killing effects of recombinant chimeric viruses against A549 cells as detected by the MTT method according to Example 5;

[0037] FIG. 8 shows the killing effects of recombinant chimeric viruses against A375 cells as detected by the MTT method according to Example 5;

[0038] FIG. 9 shows the killing effects of the recombinant chimeric viruses against liver cancer cells as detected by an Annexin V/PI method according to Example 5;

[0039] FIG. 10 shows the statistics of tumour volume of H22 tumour-bearing mice treated with recombinant chimeric viruses according to Example 6;

[0040] FIG. 11 shows the statistics of tumour weight after the H22 tumour-bearing mice are treated with the recombinant chimeric viruses according to Example 6;

[0041] FIG. 12 shows the statistics of survival rate of the H22 tumour-bearing mice treated with the recombinant chimeric viruses according to Example 6;

[0042] FIG. 13 shows the pathological observations of tumour tissues after the H22 tumour-bearing mice are treated with the recombinant chimeric viruses according to Example 6;

[0043] FIG. 14 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against HCCLM3 cells as detected by the MTT method according to Example 7;

[0044] FIG. 15 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against SK-MEL5 cells as detected by the MTT method according to Example 7;

[0045] FIG. 16 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against A549 cells as detected by the MTT method according to Example 7;

[0046] FIG. 17 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against ASPC-1 cells as detected by the MTT method according to Example 7;

[0047] FIG. 18 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against FTC133 cells as detected by the MTT method according to Example 7;

[0048] FIG. 19 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against 786-O cells as detected by the MTT method according to Example 7;

[0049] FIG. 20 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against HT1080 cells as detected by the MTT method according to Example 7;

[0050] FIG. 21 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against KYSE-150 cells as detected by the MTT method according to Example 7;

[0051] FIG. 22 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against Hela cells as detected by the MTT method according to Example 7;

[0052] FIG. 23 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against MCF7 cells as detected by the MTT method according to Example 7;

[0053] FIG. 24 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against HCT116 cells as detected by the MTT method according to Example 7; and

[0054] FIG. 25 shows the killing effects of recombinant chimeric viruses expressing exogenous genes against U87-MG cells as detected by the MTT method according to Example 7.

Detailed Description of Embodiments

[0055] Specific embodiments of the present application will be illustrated below in further detail in combination with accompanying drawings and examples for a better understanding of the solutions of the present application as well as the advantages thereof in various aspects. Nevertheless, the specific embodiments and examples described below are merely for illustrative purposes, and are not intended to limit the present application.

[0056] The experimental methods in the embodiments below are conventional methods, unless otherwise stated. Test materials used in the embodiments below are purchased from biochemical reagent stores, unless otherwise stated. For quantitative tests in the embodiments below, three repeated experiments are set up, and the results are averaged. Unless otherwise specified in the following examples, the technical means used in these examples are conventional means well-known to a person skilled in the art or common commercially-available instruments and reagents. References can be made to Molecular Cloning: A Laboratory Manual (Third Edition) (Science Press), Microbiological Experiments (Fourth Edition) (Higher Education

Press), and the manufacturer's instructions for use for the corresponding instruments and reagents, etc.

[0057] A reference mentioning "pBrLosata plasmid" is "Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumour Effect" (Ziye Pan, PLOS ONE.; Harbin Boxiang Medical Technology Development Co., Ltd.).

[0058] A reference mentioning "pBL-N plasmid", "pBL-P plasmid", and "pBL-L plasmid" is "Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy" (Fuliang Bai, Immunology letters; Harbin Boxiang Medical Technology Development Co., Ltd.).

[0059] The pBrLosata plasmid contains the NP, P, M, F, HN, and L genes of the Newcastle disease virus, with PmeI and SacII digestion recognition sites between the P gene and the M gene. The pBrLosata, pBL-N, pBL-P, and pBL-L plasmids are co-transfected to mammalian cells and cultured (with the pBL-N, pBL-P, and pBL-L plasmids as helpers, and the pBrLosata plasmid providing a virus whole-genome) to obtain a virus strain Losata.

[0060] The exogenous genes involved herein include a death receptor gene *DR5*, a tumour necrosis factor-related apoptosis-inducing ligand gene *TRAIL*, a human interleukin gene *2hIL2*, a cancer suppressor gene *P53*, a programmed death receptor 1 gene *PD1*, a suicide gene *CD*, and a murine interleukin gene *12mIL12*.

[0061] pMD19-T: purchased from TaKaRa Engineering (Dalian) Co., Ltd. (Dalian TaKaRa Bio Inc.).

[0062] BHK-21 cells (baby hamster kidney cells): purchased from ATCC.

[0063] Liver cancer cells HepG2, breast cancer cells MDA-MB-231, non-small cells lung cancer cells A549, neuroblastoma cells U251, melanoma cells

A375, liver cancer cells HCCLM3, melanoma cells SK-MEL5, pancreatic cancer cells ASPC-1, thyroid cancer cells FTC133, kidney cancer cells 786-O, neuroblastoma cells U87-MG, myosarcoma cells HT1080, esophageal cancer cells KYSE-150, uterine cancer cells Hela, breast cancer cells MCF7, and colorectal cancer cells HCT116 were purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

[0064] High-glucose DMEM medium, trypsin, Newborn calf serum (NBCS), and fetal bovine serum (FBS): purchased from GIBCO.

[0065] SPF chicken embryo: purchased from Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences.

[0066] Balb/c mice (Kunming mice): purchased from Vital River Laboratories, Beijing.

[0067] Example 1: Virus strain screening

[0068] Chicken embryo fibroblasts in a logarithmic growth phase were digested with trypsin and collected, and then seeded into a 6-well plate. Three virulent Newcastle disease virus strains F48E9, Turkey/US(ND)/43084/92 (TkND) and Game fowl/US(CA)/211472/02 (CA02) and one mesogenic and velogenic strain Anhinga (the strains were donated by Southeast Poultry Research Laboratory and stored in our laboratory, and a reference mentioning the virus strains is “Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone”. Virus Research, Volume 129, Issue 2, November 2007, Pages 182-190) infected cells at 0.1 MOI respectively, and a control group was a virus-free SPF chicken embryo allantoic fluid. After 24 h, the 6-well plate were taken out and observed under an inverted fluorescence microscope for a cell fusion effect. By analysing a syncytial formation capability, virus strains having strong fusion capability were screened out for

subsequent experiments. The results were shown in FIG. 1, in which F48E9 showed the strongest fusion-promoting capability.

[0069] Example 2: Preparation of recombinant chimeric virus

[0070] I. Construction of recombinant plasmid (taking F gene replacement as an example)

[0071] 1. The virus strain F48E9 with a stronger oncolytic effect was screened out, and the sequence of its F gene was acquired from NCBI (GenBank: AY508514.1), and overlap PCR primers were designed.

[0072] 2. The virus RNA was extracted; an F gene fragment was amplified by PCR using F-gene specific primers, linked to pMD19-T and transformed into *Escherichia coli* DH5 α ; plasmids were extracted and identified; and the correctly identified pMD19-T-F plasmids were used for the next experiment.

[0073] 3. With the PCR technique, the target fragments A and B were amplified by using the pBrLosata plasmid as a template (primers for the fragment A: P1: 5' CACGTG AAAGCGCCAGAGAAGATTCCCGGGA 3'; P2: 5' TTTGGGGCCCATCTTGCACCTGGAGGGCGCCAACCGG 3'; P3: 5' TCCAGGTGCAAGATGGGCCCCAAATCTTCTACCAATG 3'. primers for the fragment B: P6: 5' CCTCATCTGTGT TCAGATTCTTGTAAGTGGCCCTCAT 3'; P7: 5' ACAAGAATCTGAACACAGATGAGGAACGAAGGTTTCC 3'; P8: 5' GGCCTCTCAGGCCACGCGTCGCCGCGGGCCGGTT 3'). The target fragment F was amplified by using the pMD19-T-F plasmid as a template, and the fragments A, F and B were extracted by gel. Then, the fragment A-F-B of interest was amplified by the overlap PCR method using the purified fragments A, F and B as templates, and linked to a pMD19-T vector; the linking product was transformed into *Escherichia coli* DH5 α ; plasmids were extracted and identified; and the correctly identified plasmids were named as pMD19-T-A-F-B, which carry two digestion sites PmlI and SfiI.

[0074] 4. The plasmids pMD19-T-A-F-B from step 3 were digested using restriction enzymes PmlI and SfiI, and the cleaved product was extracted by gel.

[0075] 5. The pBrLosata plasmid was digested using the restriction enzymes PmlI and SfiI, and the vector was extracted by gel.

5 **[0076]** 6. The cleaved product from step 4 and the vector from step 5 was linked to obtain a recombinant chimeric plasmid pBrLosata-F. PCR and double digestion identification were performed on the recombinant chimeric plasmid; the correctly identified plasmid samples were sub-packaged and sent to Shanghai Sangon for sequencing. The sequencing results were aligned using sequence analysis software
10 DNAMAN; and the plasmid with the sequencing result consistent with a sequence of interest was named as pBrLosata-F. The nucleotide sequence of the recombinant chimeric plasmid pBrLosata-F was as set forth in SEQ ID NO:1 of the sequence listing (the nucleotide sequence at positions 7274-8935 from the 5'-terminus in SEQ ID NO: 1 was the nucleotide sequence of the F gene).

15 **[0077]** Other recombinant chimeric plasmids were constructed in the same way: pBrLosata-HN (HN gene sequence in GenBank: AY034892.1) pBrLosata-P (P gene sequence in GenBank: AF327300.1), pBrLosata-M (M gene sequence in GenBank: AF089819.1).

[0078] II. Determination of optimal insertion position for exogenous gene

20 **[0079]** 1. Restriction Enzyme cutting sites were respectively introduced to the NP/P, P/M, M/F, and F/HN sites of the pBrLosata-F plasmid using a molecular biology method. Recombinant plasmids pBrLosata-F-NP/P (AscI, SfiI), pBrLosata-F-P/M (SacII, PmeI), pBrLosata-F-M/F (HpaI, MluI), and pBrLosata-F-F/HN (HpaI, MluI) were obtained.

25 **[0080]** 2. RFP gene fragments carrying different restriction enzyme cutting sites were amplified by PCR using specific primers for a red fluorescent protein RFP

gene (red fluorescent protein RFP gene sequence in GenBank: MG719763.1), and linked to a pMD19-T vector; the linking product was transformed into Escherichia coli DH5 α ; and the plasmid was extracted and identified as carrying different digestion sites.

5 **[0081]** 3. The plasmid from step 2 was digested using a restriction enzyme, and the cleaved product was extracted by gel.

[0082] 4. The recombinant plasmid from step 1 was digested using a restriction enzyme, and the vector was extracted by gel.

10 **[0083]** 5. The cleaved product from step 3 and the vector from step 4 were linked to obtain recombinant plasmids pBrLosata-F-NP/P-RFP, pBrLosata-F-P/M-RFP, pBrLosata-F-M/F-RFP, and pBrLosata-F-F/HN-RFP.

[0084] 6. BHK-21 cells were co-transfected with the recombinant plasmid from step 5 and the helper plasmid to obtain recombinant virus rLosata-F-NP/P-RFP, rLosata-F-P/M-RFP, rLosata-F-M/F-RFP, and rLosata-F-F/HN-RFP.

15 **[0085]** 7. MCF7 cells in the logarithmic growth phase were digested with trypsin and then collected, and seeded into a 6-well plate. The cells were respectively infected with the recombinant chimeric viruses rLosata-F-NP/P-RFP, rLosata-F-P/M-RFP, rLosata-F-M/F-RFP, and rLosata-F-F/HN-RFP at 1 MOI, the parental virus rLosata was used as a control, and the control group was virus-free SPF
20 chicken embryo allantoic fluid. After 24 h, the 6-well plate was taken out, and the average fluorescence intensity of the cells infected with respective virus was detected by the flow cytometry. The results were shown in FIG. 2, showing the strongest red fluorescence intensity between P and M sites, which indicates the highest RFP expression level between the P and M sites.

25 **[0086]** III. Construction of recombinant plasmid inserted with exogenous gene (taking PD1 gene insertion as an example)

[0087] 1. Monocytes were isolated from human peripheral blood cells, and RNA was extracted and reverse-transcribed into cDNA.

[0088] According to the human PD1 sequence (AY238517.1) that has been published in GenBank, PCR primers P1 and P2 were designed using Primer Premier 5.0 software to clone the complete PD1 gene. PmeI and SacII digestion sites were designed at both ends of the primers to match the pBrLosata-F vector plasmid.

[0089] 2. The PCR product from step 1 was linked to pMD19-T and transformed into Escherichia coli; plasmids were extracted and identified; and the correctly identified pMD19-T-PD1 plasmids were used for the next experiment.

[0090] 3. The pMD19-PD1 plasmids from step 2 were digested using restriction enzymes PmeI and SacII, and the cleaved product was extracted by gel.

[0091] 4. The pBrLosata-F plasmids were digested using restriction enzymes PmeI and SacII, and the vector was extracted by gel.

[0092] 5. The cleaved product from step 3 was linked to the vector from step 4 to obtain a recombinant chimeric plasmid pBrLosata(F)-PD1, with the PD1 gene inserted between the P and M genes of the plasmid. PCR as well as PmeI and SacII double digestion identification were performed on the recombinant chimeric plasmid; the correctly identified plasmid samples were sub-packaged and sent to Shanghai Sangon for sequencing. The sequencing results were aligned using sequence analysis software DNAMAN; and the sequenced result was consistent with a sequence of interest. The PD1 nucleotide sequence of the recombinant chimeric plasmid pBrLosata(F)-PD1 was as set forth in SEQ ID NO. 6 in the sequence listing.

[0093] Other recombinant chimeric plasmids inserted with exogenous genes were constructed using the same method. The constructed recombinant chimeric plasmids were specifically as follows: pBrLosata(F)-DR5 (a DR5 sequence as set forth in SEQ ID NO: 2), pBrLosata(F)-TRAIL (a TRAIL sequence as set forth in SEQ ID

NO: 3), pBrLosata(F)-hIL2 (a hIL2 sequence as set forth in SEQ ID NO: 4) ,
pBrLosata(F)-P53 (a P53 sequence as set forth in SEQ ID NO:5), pBrLosata(F)-CD (a
CD sequence as set forth in SEQ ID NO: 7), pBrLosata(F)-mIL12 (a mIL12 sequence
as set forth in SEQ ID NO: 8), pBrLosata(F)-DR5-TRAIL (i.e., a DR5-TRAIL
combination as the exogenous gene), pBrLosata(F)-mIL12-hIL2 (i.e., a mIL12-hIL2
combination as the exogenous gene), pBrLosata(F)-P53-hIL2 (i.e., a P53-hIL2
combination as the exogenous gene), and pBrLosata(F)-PD1-hIL2 (i.e., a PD1-hIL2
combination as the exogenous gene).

[0094] IV. Preparation of recombinant chimeric virus

[0095] 1. BHK-21 cells were co-transfected respectively with the plasmid
pBrLosata the recombinant chimeric plasmids pBrLosata-HN, pBrLosata-F,
pBrLosata-P, pBrLosata-M, pBrLosata(F)-DR5, pBrLosata(F)-TRAIL,
pBrLosata(F)-hIL2, pBrLosata(F)-P53, pBrLosata(F)-PD1, pBrLosata(F)-CD,
pBrLosata(F)-mIL12, pBrLosata(F)-DR5-TRAIL, pBrLosata(F)-mIL12-hIL2,
pBrLosata(F)-P53-hIL2 and pBrLosata(F)-PD1-hIL2, together with the helper
plasmids pBL-NP, pBL-P and pBL-L (about 1×10^6 cells transfected with 2 μ g of
recombinant chimeric plasmids, 1 μ g of pBL-N plasmids, 0.5 μ g of pBL-P plasmids
and 0.25 μ g of pBL-L plasmids) . The transfected cells were placed in a 5% CO₂
environment at 37°C for static culture for 72 h.

[0096] 2. The transfected cells obtained in step 1 were repeatedly frozen and
thawed three times, centrifuged to collect the cell supernatant, then seeded into the
allantoic cavities of 9-11-day-old SPF chicken embryos. The chicken embryo allantoic
cavities were cultured for 72 h in an environment at 37°C, and the chicken embryo
allantoic fluid was collected for HA detection.

[0097] 3. The HA-positive chicken embryo allantoic liquid obtained in step
2 was passaged, seeded into the allantoic cavities of fresh 9-11-day-old SPF chicken
embryos, and cultured for 72 h in an environment at 37°C. The chicken embryo

allantoic liquid was collected for HA detection. The HA-positive chicken embryo allantoic liquid was passaged for 10 generations, and the proliferation stability of the recombinant viruses were detected.

[0098] 4. The chicken embryo allantoic liquid obtained from step 3 was taken for mass reproduction of the viruses, then seeded into the allantoic cavities of new 9-11-day-old SPF chicken embryos, and cultured for 72 h in an environment at 37°C. The chicken embryo allantoic liquid was collected for HA detection. The allantoic liquid with the HA titer greater than 2^9 was selected, mixed and sub-packaged for later use.

[0099] 5. The allantoic liquid was collected from each group for Western Blot to detect the expression of each exogenous gene. The results showed that, compared with the rLosata group, the recombinant chimeric viruses expressing the exogenous gene was capable of stably expressing the exogenous gene.

[00100] In the following description, unless otherwise specified, the recombinant chimeric viruses, the chimeric viruses and the recombinant viruses refer to the recombinant chimeric viruses prepared by the above methods. rLosata-HN, rLosata-F, rLosata-P, rLosata-M, rLosata(F)-DR5, rLosata(F)-TRAIL, rLosata(F)-hIL2, rLosata(F)-P53, rLosata(F)-PD1, rLosata(F)-CD, rLosata(F)-mIL12, rLosata(F)-DR5-TRAIL, rLosata(F)-mIL12-hIL2, rLosata(F)-P53-hIL2 and rLosata(F)-PD1-hIL2 respectively refer to the recombinant chimeric viruses prepared with the above methods by using the recombinant chimeric plasmids pBrLosata-HN, pBrLosata-F, pBrLosata-NP, pBrLosata-M, pBrLosata(F)-DR5, pBrLosata(F)-TRAIL, pBrLosata(F)-hIL2, pBrLosata(F)-P53, pBrLosata(F)-PD1, pBrLosata(F)-CD, pBrLosata(F)-mIL12, pBrLosata(F)-DR5-TRAIL, pBrLosata(F)-mIL12-hIL2, pBrLosata(F)-P53-hIL2 and pBrLosata(F)-PD1-hIL2.

[00101] In the following description, unless otherwise specified, the parental viruses refer to the Newcastle disease viruses rLosata and F48E9.

[00102] Example 3: Determination of virulence and pathogenicity of recombinant chimeric viruses

[00103] I. Determination of EID₅₀

[00104] The rescued recombinant chimeric viruses or parental viruses were serially diluted 10 times with sterilized PBS respectively. Chicken embryos were taken out from an incubator at 37°C. Six 9-11-day-old SPF chicken embryos were seeded with the viruses at each dilution (100 µL for each), and incubated in the incubator at 37°C for 4-6 days. Each chicken embryo needed to be detected by HA assay. The number of embryos infected at each dilution was recorded. The EID₅₀ of each of the recombinant chimeric viruses or parental viruses was calculated according to a Reed and Muench method.

[00105] II. Determination of TCID₅₀

[00106] 1. DF-1 cells were seeded into a 96-well microplate by using a DMEM medium containing 10% FBS and 1% antibiotics, and held in a 5% CO₂ incubator at 37°C overnight.

[00107] 2. Before the recombinant chimeric viruses and the parental viruses were seeded, the original cell culture medium added in step 1 was discarded, and 180 µL of fresh DMEM culture medium containing 10% allantoic fluid and 1% antibiotics.

[00108] 3. 20 µL of the recombinant chimeric viruses or parental viruses was seeded into the top row of cell wells; the mixture was gently pipetted up and mixed; and 20 µL of the mixture was pipetted to the lower cell wells for 10-fold serial dilution. Three replicate samples were set up for each virus.

[00109] 4. In the 5% CO₂ cell incubator at 37°C, the recombinant chimeric viruses or parental viruses were seeded and incubated for 1 h; then, the culture medium added in step 3 was discarded, and the residue was washed with PBS; and then, 200 µL

of fresh DMEM culture medium containing 10% allantoic fluid and 1% antibiotics was added.

[00110] 5. The culture continued in a 5% CO₂ cell incubator at 37°C. After 72 h, the wells with cytopathy were observed under an optical inverted microscope, the number of wells with cytopathy was recorded, and the titer of the respective virus was calculated according to the Reed and Muench method.

[00111] III. Determination of MDT

[00112] The recombinant chimeric viruses or parental viruses were serially diluted 10 times with sterilized PBS respectively. The viruses subjected to doubling dilution were seeded to six 10-day-old SPF chicken embryos (100 µL for each) via allantoic cavities, and were continuously cultured for 7 days in the incubator at 37°C. The death time and death number of the chicken embryos seeded at each dilution were checked and recorded every 12 hours. Finally, the death times of all chicken embryos seeded at the highest dilution ratio of the viruses are averaged as the MDT of the viruses in discussion.

[00113] IV. Determination of ICPI

[00114] According to the OIE standard, the recombinant chimeric viruses or parental viruses were first subjected to serial 10-fold dilution with sterilized PBS, and then intracerebrally seeded to ten 1-day-old SPF chicks (50 µL for each). Observations were continuously conducted for 10 days to record the daily morbidity and mortality of the chicks, and the intracerebral pathogenicity index of the viruses was calculated according to the Reed and Muench method.

[00115] The results of the measured virulence and pathogenicity of the recombinant chimeric viruses in Example 3 were shown in Table 1. The ICPI value of the parental virus strain F48E9 was 1.81; the ICPI values of rLosata-HN, rLosata-P and rLosata-M were significantly lower than that of F48E9, and were 0.11, 0.40, and

0.27 respectively; and the ICPI value of rLosata-F was 1.59, which is also lower than that of F48E9. The results showed that, compared with the parental virus strain F48E9, the HN, P, M and F replacements could reduce the pathogenicity of F48E9 in chickens. rLosata-F as a recombinant virus showed higher controllability and safety than F48E9.

5

Table 1 Comparison of virus titer, virulence, and pathogenicity

Virus	HA	TCID ₅₀	EID ₅₀	MDT	ICPI
rLosata	2 ⁹	2.09×10 ⁷	6.67×10 ⁹	>120 h	0.00
F48E9	2 ⁹	2.24×10 ⁸	5.13×10 ⁹	58 h	1.81
rLosata-HN	2 ⁸	1.1×10 ⁷	1×10 ⁹	>120 h	0.11
rLosata-P	2 ⁹	1×10 ⁸	4.92×10 ⁹	>120 h	0.40
rLosata-F	2 ⁹	2.24×10 ⁸	6.67×10 ⁹	62 h	1.59
rLosata- M	2 ⁹	1.62×10 ⁸	4.67×10 ⁹	>120 h	0.27
rLosata(F)-DR5	2 ⁹	4.67×10 ⁷	3.98×10 ⁹	60 h	1.57
rLosata(F)-TRAIL	2 ⁹	4.6×10 ⁷	2.29×10 ⁹	64 h	1.59
rLosata(F)-hIL2	2 ¹⁰	1.71×10 ⁸	6.67×10 ⁹	66 h	1.55
rLosata(F)-P53	2 ⁹	3.92×10 ⁷	3.37×10 ⁹	66 h	1.58
rLosata(F)-PD1	2 ¹⁰	1.92×10 ⁸	4.92×10 ⁹	64 h	1.56
rLosata(F)-CD	2 ⁹	4.11×10 ⁷	2.12×10 ⁹	64 h	1.59
rLosata(F)-mIL12	2 ⁹	3.16×10 ⁷	3.52×10 ⁹	68 h	1.54
rLosata(F)-DR5-TRAIL	2 ⁹	3.16×10 ⁷	3.61×10 ⁹	60 h	1.59
rLosata(F)-mIL12-hIL2	2 ⁹	1.61×10 ⁸	4.67×10 ⁹	66 h	1.58
rLosata(F)-P53-hIL2	2 ⁹	4.11×10 ⁷	3.92×10 ⁹	64 h	1.59
rLosata(F)-PD1-hIL2	2 ¹⁰	1.92×10 ⁸	5.13×10 ⁹	68 h	1.58

[00116] Example 4: Killing effect of recombinant chimeric virus against tumour cells as detected in cell fusion experiment

[00117] The tumour cells refer to liver cancer cells HepG2, breast cancer cells MDA-MB-231, non-small cell lung cancer cells A549, melanoma cells A375, or neuroblastoma cells U251.

10

[00118] I. Infection of tumour cells with recombinant chimeric viruses

[00119] Tumour cells in the logarithmic growth phase were digested with trypsin and then collected, and seeded into a 6-well plate. The cells were infected with the recombinant chimeric viruses rLosata-HN, rLosata-F, rLosata-P, and rLosata-M at 1 MOI respectively, the parental virus rLosata was used as a control, and a control

15

group was a virus-free SPF chicken embryo allantoic fluid. After 24 h, the 6-well plate was taken out, and observed under the fluorescent microscope for a cell fusion effect. The results could be found in FIG. 3A to FIG. 3E.

[00120] The results showed that, compared with the parental viruses, the recombinant chimeric viruses rLosata-HN, rLosata-P, and rLosata-M produced more syncytia than rLosata, but without significant difference; and the chimeric virus rLosata-F produced more syncytia than rLosata, with an extremely significant difference.

[00121] Example 5: Effect of recombinant chimeric virus on tumour cells

[00122] The tumour cells refer to liver cancer cells HepG2, breast cancer cells MDA-MB-231, non-small cell lung cancer cells A549, melanoma cells A375, or neuroblastoma cells U251.

[00123] I. Detection of inhibitory effect of recombinant chimeric virus on tumour cells by MTT method

[00124] Tumour cells in the logarithmic growth phase were digested by trypsin, and then, prepared into a cell suspension of 2×10^4 cells/mL by using the DMEM or RPMI-1640 culture medium containing 10% calf serum. The cell suspension was seeded in a 96-well plate (200 μ l per well), placed in a 5% CO₂ environment at 37°C for static culture for 24 h; the culture supernatant was discarded; and the residue was washed with a PBS buffer and then grouped. 100 μ L of chimeric viruses at 0.01 MOI, 0.1 MOI, 1 MOI, and 10 MOI were added to each group of experimental wells, respectively; 100 μ L of rLosata at 0.01 MOI, 0.1 MOI, 1 MOI, and 10 MOI was added to the control group, respectively; and 100 μ L of DMEM was added to negative control wells. After 1 h of virus infection, the virus solution was discarded, 200 μ L of PBS was added to each well for washing once; and a cell maintenance medium containing 5% serum was added for culture. After culturing for

24 h and 48 h respectively, 20 μ L of MTT solution (5 mg/mL) was added to each well and incubated for 4 h; the culture solution was discarded; 150 μ L of DMSO was added to each well; and after oscillating for 10 min, the OD value at 490 nm was measured with a microplate reader, and the cell growth inhibition rate was calculated.

5 **[00125]** Inhibition rate = (OD value of negative control treated well – OD value of experimental treated well) / OD value of negative control treated well $\times$ 100%.

10 **[00126]** The inhibition rate against HepG-2 cells could be found in FIG. 4; the inhibition rate against U251 cells could be found in FIG. 5; the inhibition rate against MDA-MB-231 cells could be found in FIG. 6; the inhibition rate against A549 cells could be found in FIG. 7; and the inhibition rate against A375 cells could be found in FIG. 8.

15 **[00127]** The results showed that both the parental virus rLosata and the chimerical viruses rLosata-HN, rLosata-F, rLosata-P, and rLosata-M showed an inhibitory effect on the above cells; the inhibitory effect of the chimeric virus Losata-F is significantly higher than that of the parental virus rLosata; the inhibitory effects of other chimeric viruses rLosata-HN, rLosata-NP, and rLosata-M are higher than that of the parental virus rLosata, without significant difference; and the killing effects of the recombinant viruses on the tumour cells were positively correlated with time and dose.

20 **[00128]** II. Killing effect of recombinant chimeric virus against liver cancer cells as detected by Annexin V/PI method

25 **[00129]** HepG2 tumour cells in the logarithmic growth phase were collected and prepared into a cell suspension of $1-10 \times 10^4$ cells/mL (containing 0.001% trypsin). The cell suspension was mixed well and added to a 6-well plate, and after the cells grew to 60-80%, group experiments were carried out.

[00130] HepG2 cells added with the virus-free SPF chicken embryo allantoic

fluid were taken as a null cell control group (control); HepG2 cells added with 1 MOI rLosata were taken as a control group; and HepG2 cells added with 1 MOI recombinant chimeric viruses were taken as experiment groups.

[00131] After 12 hours of infection, the cells ($0.5-1 \times 10^6$ cells) were digested with 0.25% trypsin, and washed twice with PBS; 500 uL of binding buffer was pipetted with a pipette to gently suspend the cells; 10 μ L of FITC-labeled Annexin-V was added and mixed well; 5 μ L of PI was then added and mixed well; immediately after 5-15 minutes of reaction in the dark, quantitative detection was carried out by flow cytometry; and at the same time, the HepG2 cells without AnnexinV-FITC and PI added were set up as a negative control.

[00132] The results could be found in FIG. 9 and showed that both the parental viruses and the recombinant chimeric viruses could induce the apoptosis of tumour cells; the effect of the virus rLosata-F was significantly stronger than that of the virus rLosata; and the effects of other recombinant chimeric viruses were not significantly different from that of the virus rLosata.

[00133] Example 6: Therapeutic effect of recombinant chimeric virus on tumours and virus safety detection

[00134] I. Therapeutic effect of recombinant chimeric virus on tumours

[00135] 1. Establishment of Balb/c mice H22 liver cancer animal model

[00136] Kunming mice of 6 weeks old were used for experiments. H22 mice liver cancer cells were seeded into the abdominal cavities of Humming mice, and after 7 days, the ascites occurred, and the mice were sacrificed by neck breakage. The ascites containing H22 cells was extracted under a sterile condition; a proper amount of PBS was added to formulate a cancer cell suspension; and the cells were counted and measured in viability, with the viable cell rate up to 95%. The cell density was adjusted to 10^6 cells/mL for later use. Subcutaneous injection was performed on each

Balb/c mice at the right groin at a dose of 0.2 mL, approximately containing 2×10^5 tumour cells. After 8-12 days, when a solid tumour with a diameter of 5-8 mm was formed, the modeling was successful, and the subsequent experiments could be carried out. The mice with the tumour diameter of 5-8 mm were selected, from which individuals with greatly varied forms and sizes were removed, and the remaining mice were taken as model mice.

[00137] 2. Therapeutic effect of recombinant chimeric virus on tumours

[00138] The model mice were randomly divided into six groups, with 15 mice in each group. They were treated as follows:

[00139] an rLosata-HN group: 0.2 mL of rLosata-HN virus solution (containing 10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 14-day treatment;

[00140] an rLosata-F group: 0.2 mL of rLosata-F virus solution (containing 10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 14-day treatment;

[00141] an rLosata-P group: 0.2 mL of rLosata-P virus solution (containing 10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 14-day treatment;

[00142] an rLosata-M group: 0.2 mL of rLosata-M virus solution (containing 10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 14-day treatment;

[00143] an rLosata group: 0.2 mL of rLosata virus solution (containing 10^7 pfu viruses) was injected into the tumours of the model mice every day for 14-day treatment; and

[00144] an allantoic fluid group (Model): 0.2 mL of allantoic fluid was injected to the tumour of each model mice every day, and treated for 14 days.

[00145] The tumour volume was measured every other day. After the treatment was completed, the mice were sacrificed, the tumours were removed and measured in terms of volume and weight (the results were shown in FIG. 10 and FIG. 11). The survival conditions of the remaining mice were observed after the treatment was completed, and the control group included normal mice without any treatment (FIG. 12). The results showed that, compared with the allantoic fluid group, both the parental viruses and the chimeric viruses showed significant inhibitory effects on the tumours; the anti-tumour effects of rLosata-P and rLosata-M were higher than that of the rLosata-HN group, without significant difference; and the inhibitory effect of rLosata-F is significantly higher than those of the above three types of chimeric viruses. Compared with the allantoic fluid group, both the parental viruses and the chimeric viruses could significantly improve the survival rate of the mice; and compared with the rLosata group, only rLosata-F could significantly improve the survival rate of the mice.

[00146] 3. Observation of pathological sections of tumours

[00147] To observe the tumour tissue cell morphology of NDV chimeric viruses and the control group after treatment, tumour tissues were acquired from each group of mice after treatment, and were prepared into tumour tissue paraffin sections following the conventional method. The morphological characteristics of tumour tissues in each treatment group were observed under a microscope, and then compared and analysed.

[00148] The results showed that after treatment, the tumour tissues from the model group were dense in structure with intact cell morphology and vigorous growth; and the tumour tissues from the rLosata virus control group undergone slight necrosis; the rLosata-HN, rLosata-P, and rLosata-M groups exhibited incomplete cell structure,

accompanied with lymphocytes infiltration to a certain extent; and the rLosata-F group exhibited loose tumour tissues and incomplete cell structure, accompanied with massive lymphocytes infiltration (See FIG.13).

[00149] II. Safety detection of recombinant chimeric viruses

5 **[00150]** Acute toxicity test

[00151] Healthy Kunming mice of 4-6 weeks old were selected, 20 mice in total including half female and half male, and the mice were divided into two groups, 10 mice in each group. The mice in the control group were fed normally. Each mouse in the experiment groups was intraperitoneally injected with 1×10^4 pfu of rLosata-F, and was observed for 48 hours after injection. If the mice under test experienced respiratory depression, unsteady limbs, paralysis symptoms, convulsions, fur trembles and other adverse reactions, and death, these mice were determined as positive.

[00152] Subacute toxicity test

15 **[00153]** Health Kunming mice of 4-6 weeks old were selected, 20 mice in total including half female and half male, and the mice were divided into two groups, 10 mice in each group. Each mouse in the experiment groups was intraperitoneally injected with 1×10^4 pfu of rLosata-F, and the mice in the control group were fed normally. The responses of the mice were continuously recorded within 4 weeks, and the observations focused on aspects such as water intake, food intake, fur colour and body weight. If everything is normal without any adverse reaction or death, these mice were determined as negative.

[00154] The results showed that the recombinant chimeric viruses had no adverse effect on the normal growth of mice, and were safe and reliable.

25 **[00155]** Example 7: Effects of recombinant chimeric viruses expressing exogenous genes on tumour cells

[00156] The tumour cells included liver cancer cells HCCLM3, melanoma cells SK-MEL5, lung cancer cells A549, pancreatic cancer cells ASPC-1, thyroid cancer cells FTC133, kidney cancer cells 786-O, neuroblastoma cells U87-MG, myosarcoma cells HT1080, esophageal cancer cells KYSE-150, uterine cancer cells
5 Hela, breast cancer cells MCF7, and colorectal cancer cells HCT116.

[00157] I. Detection of inhibitory effect of recombinant chimeric virus on tumour cells by MTT method

[00158] Tumour cells in the logarithmic growth phase were digested by trypsin, and then prepared into a cell suspension at 2×10^4 cells/mL by using a DMEM,
10 F12 or RPMI-1640 culture medium containing 10% calf serum. The cell suspension was seeded in a 96-well plate (200 μ L per well), placed in a 5% CO₂ environment at 37°C for static culture for 24 h; the culture supernatant was discarded; and the residue was washed with a PBS buffer and then grouped. 100 μ L of 0.1 MOI chimeric viruses expressing exogenous genes were added to each group of experimental wells; 0.1 MOI
15 rLosata -F was added to the control group; and 100 μ L of DMEM was added to the negative control wells. After 1 h of virus infection, the virus solution was discarded, 200 μ L of PBS was added to each well for washing once; and a cell maintenance medium containing 5% serum was added for culture. After culturing for 24 h, 20 μ L of MTT solution (5 mg/mL) was added to each well and incubated for 4 h; the culture
20 solution was discarded; 150 μ L of DMSO was added to each well; and after oscillating for 10 min, the OD value at 490 nm was measured with a microplate reader, and the cell growth inhibition rate was calculated.

[00159] Inhibition rate = (OD value of negative control treated well – OD value of experimental treated well) / OD value of negative control treated well * 100%.

[00160] The inhibition rate against HCCLM3 cells could be found in FIG. 14; the inhibition rate against SK-MEL5 cells could be found in FIG. 15; the inhibition rate against A549 cells could be found in FIG. 16; the inhibition rate against ASPC-1
25

cells could be found in FIG. 17; the inhibition rate against FTC133 cells could be found in FIG. 18; the inhibition rate against 786-O cells could be found in FIG. 19; the inhibition rate against HT1080 cells could be found in FIG. 20; the inhibition rate against KYSE-150 cells could be found in FIG. 21; the inhibition rate against Hela cells could be found in FIG. 22; the inhibition rate against MCF7 cells could be found in FIG. 23; the inhibition rate against HCT116 cells could be found in FIG. 24; and the inhibition rate against U87-MG cells could be found in FIG. 25.

[00161] The results showed that rLosata(F)-DR5, rLosata(F)-TRAIL, rLosata(F)-hIL2, rLosata(F)-P53, rLosata(F)-PD1, rLosata(F)-CD, rLosata(F)-mIL12, rLosata(F)-DR5-TRAIL, rLosata(F)-mIL12-hIL2, rLosata(F)-P53-hIL2 and rLosata(F)-PD1-hIL2a all showed inhibitory effects on the above cells, and showed higher inhibition rate against HCCLM3, SK-MEL5, FTC133, 786-O, U87-MG, and HT1080 than against A549, ASPC-1, KYSE-150, Hela, MCF7, and HCT116. Also, different virus strains did not exhibit completely identical cytotoxicity against A549, ASPC-1, KYSE-150, Hela, MCF7, and HCT116. Among these 12 types of tumour cells, rLosata(F)-DR5, rLosata(F)-TRAIL, and rLosata(F)-DR5-TRAIL showed higher inhibition rate against Hela cells; rLosata(F)-P53 and rLosata(F)-P53-hIL2 showed higher inhibition rate against A549 and ASPC-1 cells; rLosata(F)-hIL2, rLosata(F)-mIL12 and rLosata(F)-mIL12-hIL2 showed higher inhibition rate against A549, KYSE-150, and Hela cells; rLosata(F)-CD showed higher inhibition rate against A549 cells; and rLosata(F)-PD1 and rLosata(F)-PD1-hIL2 showed higher inhibition rate against A549, MCF7 and HCT116 cells.

[00162] Example 8: Therapeutic effect of recombinant chimeric virus expressing exogenous gene on tumours

[00163] 1. Balb/c 4T1 breast tumour-bearing mice were established according to the method described in Example 6.

[00164] 2. Therapeutic effect of recombinant chimeric virus on tumours

[00165] The model mice were randomly divided into 13 groups, with 10 mice in each group. These groups were treated as follows respectively:

5 **[00166]** an rLosata(F)-DR5 group: 0.1 mL of rLosata(F)-DR5 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00167] an rLosata(F)-TRAIL group: 0.1 mL of rLosata(F)-TRAIL virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

10 **[00168]** an rLosata(F)-hIL2 group: 0.1 mL of rLosata(F)-hIL2 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00169] an rLosata(F)-P53 group: 0.1 mL of rLosata(F)-P53 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

15 **[00170]** an rLosata(F)-PD1 group: 0.1 mL of rLosata(F)-PD1 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

20 **[00171]** an rLosata(F)-CD group: 0.1 mL of rLosata(F)-CD virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00172] an rLosata(F)-mIL12 group: 0.1 mL of rLosata(F)-mIL12 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00173] an rLosata(F)-DR5-TRAIL group: 0.1 mL of rLosata(F)-DR5-TRAIL

virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00174] an rLosata(F)-mIL12-hIL2 group: 0.1 mL of rLosata(F)-mIL12-hIL2 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00175] an rLosata(F)-P53-hIL2 group: 0.1 mL of rLosata(F)-P53-hIL2 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00176] an rLosata(F)-PD1-hIL2 group: 0.1 mL of rLosata(F)-PD1-hIL2 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00177] an rLosata-F group: 0.1 mL of rLosata virus solution (containing 5×10^7 pfu viruses) was injected into the tumours of the model mice every day for 21-day treatment; and

[00178] an allantoic fluid group (Model): 0.1 mL of allantoic fluid was injected to the tumour of each model mice every day, and treated for 21 days.

[00179] The tumour volume was measured every other day. After the treatment was completed, the mice were sacrificed, the tumours were removed and measured in weight (the results as shown in Table 2). The results showed that compared with the allantoic fluid group, rLosata-F and the recombinant chimeric viruses expressing the exogenous genes exhibited significant inhibitory effects on the tumours; the anti-tumour effects of rLosata(F)-DR5, rLosata(F)-TRAIL and rLosata(F)-CD are higher than that of the rLosata-F group, without significant difference; the anti-tumour effects of rLosata(F)-P53 and rLosata(F)-mIL12 are significantly higher than that of the rLosata-F treatment group; and the anti-tumour effects of rLosata(F)-hIL2 and rLosata(F)-PD1 showed extremely significant

differences from the rLosata-F group. Compared with a single-gene treatment group, a dual-gene treatment group showed a further enhanced inhibitory effect against tumours. The rLosata(F)-mIL12-hIL2 and rLosata(F)-PD1-hIL2 groups exhibited the best effect, and the tumours in several mice almost regressed after the treatment was completed.

5 Table 2 Average volume and tumour weight of recombinant chimeric viruses expressing exogenous genes after the completion of treatment

	Average volume before treatment	Average volume after the completion of treatment	Average tumour weight after the completion of treatment
Model	119.86 mm ³	2086.74 mm ³	1.43 g
rLosata-F	142.58 mm ³	1352.75 mm ³	1.05 g
rLosata(F)-DR5	156.98 mm ³	898.80 mm ³	0.96 g
rLosata(F)-TRAIL	106.97 mm ³	859.95 mm ³	0.82 g
rLosata(F)-hIL2	156.611 mm ³	412.25 mm ³	0.42 g
rLosata(F)-P53	115.59 mm ³	618.95 mm ³	0.74 g
rLosata(F)-PD1	123.55 mm ³	429.5 mm ³	0.56 g
rLosata(F)-CD	107.38 mm ³	986.08 mm ³	0.94 g
rLosata(F)-mIL12	125.63 mm ³	583.95 mm ³	0.79 g
rLosata(F)-DR5-TRAIL	116.88 mm ³	479.13 mm ³	0.39 g
rLosata(F)-mIL12-hIL2	133.55 mm ³	320.46 mm ³	0.19 g
rLosata(F)-P53-hIL2	135.61 mm ³	401.46 mm ³	0.28 g
rLosata(F)-PD1-hIL2	117.43 mm ³	359.53 mm ³	0.21 g

[00180] Example 9: Safety detection of recombinant chimeric viruses expressing exogenous genes on tumours

10 **[00181]** Healthy SPF Balb/c mice of 6 weeks old were selected and grouped, 10 mice in each group. The mice in the control group were fed normally. Each mouse in the experiment groups were intraperitoneally injected with 5×10^8 pfu (10 times the therapeutic dose) recombinant chimeric virus (rLosata(F)-DR5, rLosata(F)-TRAIL, rLosata(F)-hIL2, rLosata(F)-P53, rLosata(F)-PD1, rLosata(F)-CD, rLosata(F)-mIL12, rLosata(F)-DR5-TRAIL, rLosata(F)-mIL12-hIL2, rLosata(F)-P53-hIL2, or
15 rLosata(F)-PD1-hIL2), and then observed for 30 days. As a result, the mice with obvious adverse reactions such as listlessness occurred, ruffled fur and death were determined as positive. After the observation was completed, the serum of mice in each group was collected to detect AST, ALT and other related indicators.

[00182] The results showed that on the second day after injection, the fur of several mice in the experiment groups ruffled, and their food and water intake were not affected. After one week of continuous injections, the fur of the mice returned to normal; and after continuous observation for one month, none of the mice in each experimental group showed obvious adverse reactions such as listlessness, ruffled fur and death. After the observation was completed, the serum of mice in each group was collected to detect AST, ALT, BUN, CREA and other related indicators by ELISA. The results showed that compared with normal mice, the activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as well as the concentrations of blood urea nitrogen (BUN) and serum creatinine (CREA) in each experiment group slightly increased, without significant difference. The results indicated that the chimeric virus treatment did not induce liver and kidney damage and serious toxic or side effects.

[00183] Finally, it should be noted that the above-mentioned examples are obviously examples given for the purpose of clearly illustrating the present application, and are not intended to limit the embodiments. For a person skilled in the art, other different forms of changes or variations can also be made based on the above description. It is unnecessary or impossible to exhaustively list all the embodiments herein. Furthermore, any obvious changes or variations derived herefrom shall still fall within the protection scope of the present application.

Sequence Listing

<110> JIANGSU KANIONREAL BIOMEDICAL TECHNOLOGY CO., LTD

<120> RECOMBINANT NEWCASTLE DISEASE VIRUS AND PREPARATION METHOD, RECOMBINANT PLASMID, AND USE THEREFOR

<130> 191071P1

<160> 8

<170> SIPOSequenceListing 1.0

<210> 1

<211> 18391

<212> DNA

<213> Artificial Sequence

<220>

<221> gene

<222> (7274)..(8935)

<400> 1

ctggcgtaat	agcgaagagg	cccgccaccga	tcgcccttcc	caacagttgc	gtagcctgaa	60
tggcgaatgg	gacgcgccct	gtagcggcgc	attaagcgcg	gcgggtgtgg	tggttacgcg	120
cagcgtgacc	gctacacttg	ccagcgccct	agcgcccgcg	cctttcgctt	tcttcccttc	180
ctttctcgcc	acgttcgccg	gctttccccg	tcaagctcta	aatcgggggc	tccctttagg	240
gttccgattt	agtgctttac	ggcacctcga	ccccaaaaa	cttgattagg	gtgatggttc	300
acgtagtggg	ccatcgccct	gatagacggg	ttttcgccct	ttgacgttgg	agtccacgtt	360
ctttaatagt	ggactcttgt	tccaaactgg	aacaacactc	aaccctatct	cggtctattc	420
ttttgattta	taagggtatt	tgccgatttc	ggcctattgg	ttaaaaaatg	agctgattta	480
acaaaaattt	aacgcgaatt	ttaacaaaat	attaacgttt	acaatttcag	gtggcacttt	540
tcgggggaaat	gtgcgcggaa	cccctatttg	tttatttttc	ttaatacatt	caaatatgta	600
tccgctcatg	agacaataac	cctgataaat	gcttcaataa	tattgaaaaa	ggaagagtat	660
gagtattcaa	catttccgtg	tcgcccttat	tccctttttt	gcggcatttt	gccttcctgt	720
ttttgctcac	ccagaaacgc	tggtgaaagt	aaaagatgct	gaagatcagt	tggtgtcacg	780
agtgggttac	atcgaactgg	atctcaacag	cggtaaagtc	cttgagagtt	ttcgccccga	840
agaacgtttt	ccaatgatga	gcacttttaa	agttctgcta	tgtggcgcg	tattatccc	900
tattgacgcc	gggcaagagc	aactcggctc	ccgcatacac	tattctcaga	atgacttggt	960
tgagtactca	ccagtcacag	aaaagcatct	tacggatggc	atgacagtaa	gagaattatg	1020
cagtgtgtcc	ataagcatga	gtgataaac	tgcggccaac	ttacttctga	caacgatcgg	1080
aggaccgaag	gagctaaccg	ctttttttca	caacatgggg	gatcatgtaa	ctcgccttga	1140
tcgttgggaa	ccggagctga	atgaagccat	accaaacgac	gagcgtgaca	ccacgatgcc	1200
tgtagcaatg	gcaacaacgt	tgcgcaaa	attaactggc	gaactactta	ctctagcttc	1260
ccggcaacaa	ttaatagact	ggatggaggc	ggataaaagt	gcaggaccac	ttctgcgctc	1320
ggcccttccg	gctggctggt	ttattgctga	taaatctgga	gccggtgagc	gtgggtctcg	1380
cggtatcatt	gcagcactgg	ggccagatgg	taagccctcc	cgtatcgtag	ttatctacac	1440
gacgggcagt	caggcaacta	tggatgaacg	aaatagacag	atcgctgaga	taggtgcctc	1500
actgattaag	catttgtaac	tgtcagacca	agtttactca	tatatacttt	agattgattt	1560
aaaacttcat	ttttaattta	aaaggatcta	ggtgaagatc	ctttttgata	atctcatgac	1620
caaaatccct	taacgtgagt	tttcgttcca	ctgagcgtca	gaccccgtag	aaaagatcaa	1680
aggatcttct	tgagatcctt	tttttctg	cgtaatctgc	tgcttgcaaa	caaaaaaacc	1740
accgctacca	gcgggtggtt	gtttgccgga	tcaagagcta	ccaactcttt	ttccgaaggt	1800

aactggcttc	agcagagcgc	agataccaaa	tactgtcctt	ctagtgtagc	cgtagttagg	1860
ccaccacttc	aagaactctg	tagcaccgcc	tacatacctc	gctctgctaa	tcctgttacc	1920
agtggctgct	gccagtggcg	ataagtcgtg	tcttaccggg	ttggactcaa	gacgatagtt	1980
accggataag	gcgcagcggg	cgggctgaac	gggggggttcg	tgcacacagc	ccagcttgga	2040
gcgaacgacc	tacaccgaac	tgagatacct	acagcgtgag	cattgagaaa	gcgccacgct	2100
tcccgaaggg	agaaaaggcgg	acaggtatcc	ggtaagcggc	agggctcgaa	caggagagcg	2160
cacgagggag	cttccagggg	ggaacgcctg	gtatctttat	agtcctgtcg	ggtttcgcca	2220
cctctgactt	gagcgtcgat	ttttgtgatg	ctcgtcaggg	gggccgagcc	tatggaaaaa	2280
cgccagcaac	gcggcctttt	tacggttcct	ggccttttgc	tggccttttg	ctcacatgtt	2340
ctttcctgcg	ttatccccctg	attctgtgga	taaccgtatt	accgcctttg	agtgagctga	2400
taccgctcgc	cgacagccgaa	cgaccgagcg	cagcgagtca	gtgagcgagg	aagcgggaaga	2460
gcgcccataa	cgcaaaccgc	ctctccccgc	gcgttggccg	attcattaat	gcagctggca	2520
cgacaggttt	cccgactgga	aagcgggcag	tgagcgcaac	gcaattaatg	tgagttacct	2580
cactcattag	gcaccccagg	ctttacactt	tatgcttccg	gctcctatgt	tgtgtggaat	2640
tgtgagcggg	taacaatttc	acacaggaaa	cagctatgac	catgattacg	ccaagctcgg	2700
aagcggccgc	taatacgact	cactataggg	accaaacaga	gaatccgtaa	gttacgataa	2760
aaggcgaagg	agcaattgaa	gtcgcacggg	tagaagggtg	gaatctcgag	tgcgagcccg	2820
aagcacaac	tcgagaaagc	cttctgccaa	catgtcttcc	gtatttgatg	agtacgaaca	2880
gctcctcgcg	gctcagactc	gccccaatgg	agctcatgga	ggggggagaaa	aaggggagtac	2940
cttaaaaagta	gacgtcccgg	tattcactct	taacagtgat	gaccagaag	atagatggag	3000
ctttgtggta	ttctgcctcc	ggattgctgt	tagcgaagat	gccaacaaac	cactcaggca	3060
aggtgctctc	atatctcttt	tatgctccca	ctcacaggta	atgaggaacc	atgttgccct	3120
tgacgggaaa	cagaatgaag	ccacattggc	cgtgcttgag	attgatggct	ttgccaacgg	3180
cacgccccag	ttcaacaata	ggagtggagt	gtctgaagag	agagcacaga	gatttgcgat	3240
gatagcagga	tctctccctc	gggcatgcag	caacggaacc	ccgttcgtca	cagccggggc	3300
cgaagatgat	gcaccagaag	acatcaccca	taccctggag	aggatcctct	ctatccaggc	3360
tcaagtatgg	gtcacagtag	caaaagccat	gactgcgtat	gagactgcag	atgagtcgga	3420
aacaaggcga	atcaataagt	atatgcagca	aggcagggtc	caaaagaaat	acatcctcta	3480
ccccgtatgc	aggagcacia	tccaactcac	gatcagacag	tctcttgag	tccgcattct	3540
tttggttagc	gagctcaaga	gaggccgcaa	cacggcaggt	ggtacctcta	cttattataa	3600
cctggtaggg	gacgtagact	catacatcag	gaataccggg	cttactgcat	tcttcttgac	3660
actcaagtac	ggaatcaaca	ccaagacatc	agcccttgca	cttagtagcc	tctcaggcga	3720
catccagaag	atgaagcagc	tcatgcgttt	gtatcggatg	aaaggagata	atgcgccgta	3780
catgacatta	cttggtgata	gtgaccagat	gagctttgcg	cctgccgagt	atgcacaact	3840
ttactccttt	gccatgggta	tggcatcagt	cctagataaa	ggtactggga	aataccaatt	3900
tgccagggac	tttatgagca	catcattctg	gagacttgga	gtagagtacg	ctcaggctca	3960
gggaagtagc	attaacgagg	atatggctgc	cgagctaaag	ctaaccag	cagcaaggag	4020
gggcctggca	gctgctgcc	aacgggtctc	cgaggagacc	agcagcatag	acatgcctac	4080
tcaacaagtc	ggagtcctca	ctgggcttag	cgaggggggg	tcccaagctc	tacaaggcgg	4140
atcgaataga	tcgcaagggc	aaccagaagc	cggggatggg	gagacccaat	tcctggatct	4200
gatgagagcg	gtagcaaata	gcatgaggga	ggcgccaaac	tctgcacagg	gcactcccca	4260
atcggggcct	ccccaaactc	ctgggcatc	ccaagataac	gacaccgact	gggggtattg	4320
atggacaaaa	ccagcctgc	ttccacaaaa	acatcccaat	gccctcacc	gtagtcgacc	4380
cctcgatttg	cggctctata	tgaccacacc	ctcaaacaaa	catccccctc	tttctctcct	4440
ccccctgctg	tacaactccg	cacgccctag	ataccacagg	cacaatgcgg	ctcactaaca	4500
atcaaaaacag	agccgaggga	attagaaaaa	agtacgggta	gaagagggat	attcagagat	4560
cagggaagtc	ctcccgagtc	tctgctctct	cctctacctg	atagaccagg	acaaacatgg	4620
ccacctttac	agatgcagag	atcgacgagc	tatttgagac	aagtggaaact	gtcattgaca	4680
acataattac	agcccagggt	aaaccagcag	agactgttgg	aaggagtgca	atcccacaag	4740
gcaagaccaa	ggtgctgagc	gcagcatggg	agaagcatgg	gagcatccag	ccaccggcca	4800
gtcaagacaa	ccccgatcga	caggacagat	ctgacaaaca	accatccaca	cccagacaaa	4860
cgaccccgca	tgacagcccg	ccggccacat	ccgccgacca	gccccccacc	caggccacag	4920
acgaagccgt	cgacacacag	ctcaggaccg	gagcaagcaa	ctctctgctg	ttgatgcttg	4980

acaagctcag	caataaatcg	tccaatgcta	aaaagggccc	atggtcgagc	ccccaagagg	5040
ggaatcacca	acgtccgact	caacagcagg	ggagtcaacc	cagtcgcgga	aacagtcagg	5100
aaagaccgca	gaaccaagtc	aaggccgccc	ctggaaacca	gggcacagac	gtgaacacag	5160
catatcatgg	acaatgggag	gagtcacaac	tatcagctgg	tgcaaccctt	catgctctcc	5220
gatcaaggca	gagccaagac	aatacccttg	tatctgcgga	tcattgtccag	ccacctgtag	5280
actttgtgca	agcgatgatg	tctatgatgg	aggcgatatc	acagagagta	agtaagggtt	5340
actatcagct	agatcttgtc	ttgaaacaga	catcctccat	ccctatgatg	cgggtccgaaa	5400
tccaacagct	gaaaacatct	gttgcaagtca	tggaagccaa	cttggggaatg	atgaagattc	5460
tggatccccg	ttgtgccaac	atttcattctc	tgagtgatct	acgggcagtt	gcccgatctc	5520
acccggtttt	agtttcaggc	cctggagacc	cctctcccta	tgtgacacaa	ggaggcgaaa	5580
tggcacttaa	taaactttcg	caaccagtg	cacatccatc	tgaattgatt	aaacccgcca	5640
ctgcatgcgg	gcctgatata	ggagtggaaa	aggacactgt	ccgtgcattg	atcatgtcac	5700
gccaatgca	cccagattct	tcagccaagc	tcctaagcaa	gttagatgca	gccgggtcga	5760
tcgaggaaat	caggaaaatc	aagcgccttg	ctctaaatgg	ctaattacta	ctgccacacg	5820
tagcgggtcc	ctgtccactc	ggcatcacac	ggaatctgca	ccgagttccc	ccccgcagac	5880
ccaaggtcca	actctccaag	cggcaatcct	ctctcgcttc	ctcagcccca	ctgaatgatc	5940
gcgtaaccgt	aattaatcta	gctacattta	agattaagaa	aaaatacggg	tagaattgga	6000
gtgccccaat	tgtgccaaga	tggactcatc	taggacaatt	gggctgtact	ttgattctgc	6060
ccattcttct	agcaacctgt	tagcattttcc	gatcgtccta	caagacacag	gagatgggaa	6120
gaagcaaatc	gccccgcaat	ataggatcca	gcgccttgac	ttgtggactg	atagtaagga	6180
ggactcagta	ttcatcacca	cctatggatt	catctttcaa	gttgggaatg	aagaagccac	6240
tgtcggcatg	atcgatgata	aaccacaagc	cgagttactt	tccgctgcga	tgctctgcct	6300
aggaagcgtc	ccaaataacc	gagaccttat	tgagctggca	agggcctgtc	tcactatgat	6360
agtcacatgc	aagaagagtg	caactaatac	tgagagaatg	gttttctcag	tagtgcaggc	6420
accccaagtg	ctgcaaagct	gtagggttgt	ggcaaacaaa	tactcatcag	tgaatgcagt	6480
caagcacgtg	aaagcgccag	agaagattcc	cgggagtgga	accctagaat	acaaggtgaa	6540
ctttgtctcc	ttgactgtgg	taccgaagaa	ggatgtctac	aagatcccag	ctgcagtatt	6600
gaaggtttct	ggctcgagtc	tgtacaatct	tgcgctcaat	gtcactatta	atgtggagggt	6660
agacccgagg	agtcctttgg	ttaaatctct	gtctaagtct	gacagcggat	actatgctaa	6720
cctcttcttg	catattggac	ttatgaccac	cgtagatagg	aagggaaga	aagtgcattt	6780
tgacaagctg	gaaaagaaaa	taaggagcct	tgatctatct	gtcgggctca	gtgatgtgct	6840
cgggccttcc	gtgttggtaa	aagcaagagg	tgcacggact	aagcttttgg	cacctttctt	6900
ctctagcagt	gggacagcct	gctatcccat	agcaaagtct	tctcctcagg	tggccaagat	6960
actctggagt	caaaccgcgt	gcctgcggag	cgtaaaaatc	attatccaag	caggtaccca	7020
acgcgtgtgc	gcagtgaccg	ccgaccacga	ggttacctct	actaagctgg	agaaggggca	7080
cacccttgcc	aaatacaatc	cttttaagaa	ataagctgcg	tctctgagat	tgcgctccgc	7140
ccactcacc	agatcatcat	gacacaaaaa	actaatctgt	cttgattatt	tacagttagt	7200
ttacctgtct	atcaagttag	aaaaaacacg	ggtagaagat	tctggatccc	ggttggcgcc	7260
ctccagggtc	aagatgggcc	ccaaatcttc	taccaatgtc	ccagcacctc	tgatgctgac	7320
cgtcaggatt	gcgctggcac	tgagctgtgt	ccgtctgaca	aattctctcg	atggaaggcc	7380
tcttgacagt	gcagggattg	tagtaacggg	agacaaagca	gtcaacatat	acacctcatc	7440
tcagacaggg	tcaataatag	tcaagttact	cccaaatatg	cctaaggata	aagaggcgtg	7500
tgcaaaagcc	ccgttgagg	catacaacag	gacactgact	actttgctca	cccccttgg	7560
tgattctatc	cgcaggatac	aagagtctgc	gactacgtcc	ggaggaagga	ggcagagacg	7620
ctttataggt	gccattatcg	gcagtgtagc	tcttgggggt	gccacagatg	cccagataac	7680
agcagcctca	gctctgatac	aagccaacca	gaatgctgcc	aacatcctcc	ggcttaaaga	7740
gagcattgct	gcaactaatg	aagctgtaca	tgaagtcact	gacggattat	cgcaactagc	7800
agtggcagtt	gggaagatgc	agcagtttgt	taatgaccag	tttaataaca	cagctcagga	7860
attggactgt	ataaaaaatta	cacagcaggt	tggtgtagaa	ctcaacctgt	acctaactga	7920
attgactaca	gtattcgggc	cacaaatcac	ttcccctgcc	ttactcagc	tgactatcca	7980
ggcgctttac	aatctagctg	gtggtaatat	ggattatttg	ttgactaagt	taggtgttgg	8040
gaacaaccaa	ctcagctcat	taatcggtag	cggcttgatc	accggtaac	ctattctgta	8100
cgattcacag	actcaactct	taggtatata	ggtaacttta	ccctcagtcg	gtaacctaaa	8160

taatatgcgt	gctacctact	tggagacctt	gtctgtgaagc	acaaccaagg	gatttgcctc	8220
agcacttgtc	ccaaaagtgg	tgacacaggt	cgggtctgtg	atagaggaac	ttgacacctc	8280
atactgtgta	gagaccgatt	tggatttata	ttgtacaaga	atagtacat	tccttatgtc	8340
tccttggtatt	tattcctgtc	tgagcggtaa	tacatcagct	tgcatgtatt	caaagactga	8400
aggtgcactt	actacgccat	atatgactat	caagggtca	gttattgcca	attgcaagat	8460
gacaacatgc	agatgtgcag	accctccggg	tatcatatcg	caaaattatg	gagaagctgt	8520
gtctctaata	gataggcact	catgcaatgt	cttatcctta	gacgggataa	ctttgaggct	8580
cagtggagaa	tttgacgtaa	cttatcaaaa	gaatatctca	atattagatt	ctcaggtaat	8640
agtacagggc	aatctcgata	tctcaactga	acttgggaa	gtcaacaact	cgataagtaa	8700
tgctttggat	aagttagagg	aaagcaatag	caaacttgac	aaagtcaatg	tcaagctgac	8760
cggcacgtct	gctctcatta	cctatatagt	tttaactatc	atatctcttg	tttgtggtat	8820
acttagcctg	gttctagcat	gctatctgat	gtataagcaa	aaggcgcaac	aaaagacctt	8880
attatggctt	gggaataata	ccctaaatca	gatgagggcc	actacaagaa	tctgaacaca	8940
gatgaggaac	gaagggttcc	ctaataagtaa	tttgtgtgaa	agttctggta	gtctgtcagt	9000
taagaaaaaa	tacgggtaga	aggttaaccg	gcccgcggcg	acgcgtggcc	tgagaggcct	9060
tcagagagtt	aagaaaaaac	taccggttgt	agatgaccaa	aggacgatat	acgggtagaa	9120
cggtaagaga	ggccgcccc	caattgagag	ccaggcttca	caacctccgt	tctaccgctt	9180
caccgacaac	agtcctcaat	catggaccgc	gccgttagcc	aagttgcgtt	agagaatgat	9240
gaaagagagg	caaaaaatac	atggcgcttg	atattccgga	ttgcaatctt	attcttaaca	9300
gtagtgacct	tggtatatac	tgtagcctcc	cttttatata	gcatgggggc	tagcacacct	9360
agcgatcttg	taggcatacc	gactaggatt	tccagggcag	aagaaaagat	tacatctaca	9420
cttggttcca	atcaagatgt	agtagatagg	atatataagc	aagtggccct	tgagtctccg	9480
ttggcattgt	taaatactga	gaccacaatt	atgaacgcaa	taacatctct	ctcttatcag	9540
attaatggag	ctgcaaacaa	cagtgggtgg	ggggcaccta	tccatgacct	agattatata	9600
ggggggatag	gcaaagaact	cattgtagat	gatgctagt	atgtcacatc	attctatccc	9660
tctgcatttc	aagaacatct	gaattttatc	ccggcgccct	ctacaggatc	aggttgact	9720
cgaataccct	catttgacat	gagtgtctac	cattactgct	acaccataa	tgtaatat	9780
tctggatgca	gagatcactc	acattcatat	cagtatttag	cacttggtgt	gctccggaca	9840
tctgcaacag	ggagggtatt	cttttctact	ctgcgttcca	tcaacctgga	cgacacccaa	9900
aatcggaagt	cttgacgtgt	gagtgtcaact	cccctgggtt	gtgatatgct	gtgctcgaaa	9960
gtcacggaga	cagaggaaga	agattataac	tcagctgtcc	ctacgcggat	ggtacatggg	10020
aggttagggg	tcgacggcca	gtaccacgaa	aaggacctag	atgtcacaac	attattcggg	10080
gactgggtgg	ccaactaccc	aggagtaggg	ggtggatctt	ttattgacag	ccgcgtatgg	10140
ttctcagctc	acggagggtt	aaaacccaat	tcaccagtg	acactgtaca	ggaagggaaa	10200
tatgtgatat	acaagcgata	caatgacaca	tgcccagatg	agcaagacta	ccagattcga	10260
atggccaagt	cttcgtataa	gcctggacgg	tttggtggga	aacgcataca	gcaggctatc	10320
ttatctatca	aggtgtcaac	atccttaggc	gaagaccg	tactgactgt	accgccaac	10380
acagtacac	tcatgggggc	cgaaggcaga	attctcacag	tagggacatc	tcatttcttg	10440
tatcaacgag	ggtcatcata	cttctctccc	gcgttattat	atcctatgac	agtcagcaac	10500
aaaacagcca	ctcttcatag	tccttataca	ttcaatgcct	tcactcggcc	aggtagtatc	10560
ccttgccagg	cttcagcaag	atgccccaac	tcgtgtgtta	ctggagtcta	tacagatcca	10620
tatcccctaa	tcttctatag	aaaccacacc	ttgcgagggg	tattcgggac	aatgcttgat	10680
ggtgtacaag	caagacttaa	ccctgcgtct	gcagtattcg	atagcacatc	ccgcagtcgc	10740
attactcgag	tgagttcaag	cagtacaaa	gcagcataca	caacatcaac	ttgttttaaa	10800
gtggtcaaga	ctaataagac	ctattgtctc	agcattgctg	aaatatctaa	tactctcttc	10860
ggagaattca	gaatcgtccc	gttactagtt	gagatcctca	aagatgacgg	ggttagagaa	10920
gccaggctctg	gctagttgag	tcaattataa	aggagttgga	aagatggcat	tgtatcacct	10980
atcttctg	acatcaagaa	tcaaaccgaa	tgccggcgcg	tgctcgaatt	ccatgttgcc	11040
agttgaccac	aatcagccag	tgctcatg	atcagattaa	gccttgtaaa	tagtctcttg	11100
attaagaaaa	aatgtaagt	gcaatgagat	acaaggcaaa	acagctcatg	gtaataata	11160
cgggtaggac	atggcgagct	ccggtcctga	aagggcagag	catcagatta	tcctaccaga	11220
gtcacacctg	tcttcacat	tggtcaagca	caaactactc	tattactgga	aattaactgg	11280
gctaccgctt	cctgatgaat	gtgacttcga	ccacctcatt	ctcagccgac	aatggaaaaa	11340

aatacttgaa	tcggcctctc	ctgatactga	gagaatgata	aaactcggaa	gggcagtaca	11400
ccaaactctt	aaccacaatt	ccagaataac	cggagtgtct	caccccaggt	gtttagaaga	11460
actggctaatt	attgaggtcc	cagattcaac	caacaaattt	cggaagattg	agaagaagat	11520
ccaaattcac	aacacgagat	atggagaact	gttcacaagg	ctgtgtacgc	atatagagaa	11580
gaaactgctg	gggtcatctt	ggtctaacaa	tgtccccggg	tcagaggagt	tcagcagcat	11640
tcgtacggat	ccggcattct	ggtttcactc	aaaatgggtc	acagccaagt	ttgcatggct	11700
ccatataaaa	cagatccaga	ggcatctgat	ggtggcagct	aggacaaggt	ctgcggccaa	11760
caaattgggtg	atgctaacc	ataaggtagg	ccaagtcttt	gtcactcctg	aacttgtcgt	11820
tgtgacgcat	acgaatgaga	acaagttcac	atgtcttacc	caggaacttg	tattgatgta	11880
tgcagatatg	atggagggca	gagatatggt	caacataata	tcaaccacgg	cgggtgcatct	11940
cagaagctta	tcagagaaaa	ttgatgacat	tttgcggtta	atagacgctc	tggcaaaaaga	12000
cttgggtaat	caagtctacg	atgttgatc	actaatggag	ggatttgcat	acggagctgt	12060
ccagctactc	gagccgtcag	gtacatttgc	aggagatttc	ttcgcatcca	acctgcagga	12120
gcttaaagac	attctaattg	gcctcctccc	caatgatata	gcagaatccg	tgactcatgc	12180
aatcgctact	gtattctctg	gtttagaaca	gaatcaagca	gctgagatgt	tgtgtctgtt	12240
gcgtctgtgg	ggtcacccac	tgcttgagtc	ccgtattgca	gcaaaggcag	tcaggagcca	12300
aatgtgcgca	ccgaaaatgg	tagactttga	tatgatcctt	caggtactgt	ctttcttcaa	12360
gggaacaatc	atcaacgggt	acagaaagaa	gaatgcaggt	gtgtggccgc	gagtcaaagt	12420
ggatacaata	tatgggaagg	tcattgggca	actacatgca	gattcagcag	agatttcaca	12480
cgatatcatg	ttgagagagt	ataagagttt	atctgcactt	gaatttgagc	catgtataga	12540
atatgaccct	gtcaccaacc	tgagcatggt	cctaaaagac	aaggcaatcg	cacaccccaa	12600
cgataattgg	cttgccctcg	ttaggcggaa	ccttctctcc	gaagaccaga	agaaacatgt	12660
aaaagaagca	acttcgacta	atcgccctct	gatagagttt	ttagagtcaa	atgattttga	12720
tccatataaaa	gagatggaat	atctgacgac	ccttgagtac	ccttagagatg	acaatgtggc	12780
agtatcatac	tcgctcaagg	agaaggaagt	gaaagttaat	ggacggatct	tcgctaagct	12840
gacaaagaag	ttaaggaact	gtcaggtgat	ggcgggaagg	atcctagccg	atcagattgc	12900
acctttcttt	caggggaaatg	gagtcattca	ggatagcata	tccttgacca	agagtatgct	12960
agcgatgagt	caactgtctt	ttaacagcaa	taagaaacgt	atcactgact	gtaaagaaag	13020
agtatcttca	aaccgcaatc	atgatccgaa	aagcaagaac	cgtcggagag	ttgcaacctt	13080
cataacaact	gacctgcaaa	agtactgtct	taattggaga	tatcagacaa	tcaaattgtt	13140
cgctcatgcc	atcaatcagt	tgatgggcct	acctcacttc	ttcgaatgga	ttcacctaag	13200
actgatggac	actacgatgt	tcgtaggaga	ccctttcaat	cctccaagtg	accctactga	13260
ctgtgacctc	tcaagagtcc	ctaattgatga	catatatatt	gtcagtgcca	gaggggggtat	13320
cgaaggatta	tgccagaagc	tatggacaat	gatctcaatt	gctgcaatcc	aacttgctgc	13380
agctagatcg	cattgtcgtg	ttgcctgtat	ggtacagggt	gataatcaag	taatagcagt	13440
aacgagagag	gtaagatcag	acgactctcc	ggagatgggtg	ttgacacagt	tgcatcaagc	13500
cagtataaat	ttcttcaagg	aattaattca	tgtcaatcat	ttgattggcc	ataatttgaa	13560
ggatcgtgaa	accatcaggt	cagacacatt	cttcatatac	agcaaacgaa	tcttcaaaga	13620
tggagcaatc	ctcagtcaag	tcctcaaaaa	ttcatctaaa	ttagtgtctag	tgtcaggtga	13680
tctcagttaa	aacaccgtaa	tgtcctgtgc	caacattgcc	tctactgtag	cacggctatg	13740
cgagaacggg	cttcccaaag	acttctgtta	ctatttaaac	tatataatga	gttgtgtgca	13800
gacatacttt	gactctgagt	tctccatcac	caacaattcg	caccccgatc	ttaatcagtc	13860
gtggattgag	gacatctctt	ttgtgcactc	atatgttctg	actcctgccc	aattagggggg	13920
actgagtaac	cttcaatact	caaggctcta	cactagaaat	atcggtgacc	cggggactac	13980
tgcttttgca	gagatcaagc	gactagaagc	agtgggatta	ctgagtccta	acattatgac	14040
taatattctta	actaggccgc	ctgggaatgg	agattgggcc	agtctgtgca	acgaccata	14100
ctctttcaat	tttgagactg	ttgcaagccc	aaatattgtt	cttaagaaac	atacgcaaag	14160
agtcctatct	gaaacttgtt	caaatccctt	attgtctgga	gtgcacacag	aggataatga	14220
ggcagaagag	aaggcattgg	ctgaattctt	gcttaatcaa	gaggtgattc	atccccgcgt	14280
tgcgcatgcc	atcatggagg	caagctctgt	aggtaggaga	aagcaaattc	aagggccttgt	14340
tgacacaaca	aacaccgtaa	ttaagattgc	gcttactagg	aggccattag	gcatcaagag	14400
gctgatgcgg	atagtcaatt	attctagcat	gcatgcaatg	ctgttttagag	acgatgtttt	14460
ttcctccagt	agatccaacc	accccttagt	ctcttcta	atgtgttctc	tgacactggc	14520

agactatgca	cggaatagaa	gctggtcacc	tttgacggga	ggcaggaaaa	tactgggtgt	14580
atctaatacct	gatacgatag	aactcgtaga	gggtgagatt	cttagtgtaa	gcggagggtg	14640
tacaagatgt	gacagcggag	atgaacaatt	tacttggttc	catcttccaa	gcaatataga	14700
attgaccgat	gacaccagca	agaatcctcc	gatgagggtta	ccatatctcg	ggtcaaagac	14760
acaggagagg	agagctgcct	cacttgcaaa	aatagctcat	atgtcgccac	atgtaaaggc	14820
tgccctaagg	gcatcatccg	tgttgatctg	ggcttatggg	gataatgaag	taaattggac	14880
tgctgctctt	acgattgcaa	aatctcgggtg	taatgtaaac	ttagagtatc	ttcggttact	14940
gtccccctta	cccacggctg	ggaatcttca	acatagacta	gatgatggta	taactcagat	15000
gacattcacc	cctgcatctc	tctacagggt	gtcaccttac	attcacatat	ccaatgattc	15060
tcaaaggctg	ttcactgaag	aaggagtcaa	agaggggaa	gtggtttacc	aacagatcat	15120
gctcttgggt	ttatctctaa	tcgaatcgat	ctttccaata	acaacaacca	ggacatatga	15180
tgagatcaca	ctgcacctac	atagtaaatt	tagttgctgt	atcagagaag	cacctgttgc	15240
ggttcctttc	gagctacttg	gggtgggtacc	ggaactgagg	acagtgacct	caaataagtt	15300
tatgtatgat	cctagccctg	tatcggagggtg	agactttgctg	agacttgact	tagctacttt	15360
caagagttat	gagcttaatc	tggagtcata	tcccacgata	gagctaata	acattctttc	15420
aatatccagc	gggaagttga	ttggccagtc	tgtggtttct	tatgatgaag	atacctccat	15480
aaagaatgac	gccataatag	tgtatgacaa	taccgaaat	tggatcagtg	aagctcagaa	15540
ttcagatgtg	gtccgcctat	ttgaatatgc	agcacttgaa	gtgctcctcg	actgttctta	15600
ccaactctat	tacctgagag	taagaggcct	agacaatatt	gtcttatata	tgggtgattt	15660
atacaagaat	atgccaggaa	ttctactttc	caacattgca	gctacaatat	ctcatcccgt	15720
cattcattca	aggttacatg	cagtgggcct	ggtcaacct	gacggatcac	accaacttgc	15780
agatacggat	tttatcgaaa	tgtctgcaaa	actattagta	tcttgacccc	gacgtgtgat	15840
ctccggctta	tattcaggaa	ataagtatga	tctgctgttc	ccatctgtct	tagatgataa	15900
cctgaatgag	aagatgcttc	agctgatatc	ccggttatgc	tgtctgtaca	cgggtactctt	15960
tgctacaaca	agagaaatcc	cgaaaataag	aggcttaact	gcagaagaga	aatgttcaat	16020
actactgag	tatttactgt	cggatgctgt	gaaaccatta	cttagtccc	atcaagttag	16080
ctctatcatg	tctcctaaca	taattacatt	cccagcta	ctgtactaca	tgtctcggaa	16140
gagcctcaat	ttgatcagggt	aaaggaggga	cagggatact	atcctggcgt	tgttgttccc	16200
ccaagagcca	ttattagagt	tcccttctgt	gcaagatatt	ggtgctcgag	tgaaagatcc	16260
attcacccga	caacctgcgg	catttttgca	agagttagat	ttgagtgtc	cagcaaggta	16320
tgacgcattc	acacttagtc	agattcatcc	tgaactcaca	tctccaaatc	cggaggaaga	16380
ctacttagta	cgatacttgt	tcagagggt	agggactgca	tcttctctt	ggtataaggc	16440
atctcatctc	ctttctgtac	ccgaggtaag	atgtgcaaga	cacgggaact	ccttatactt	16500
agctgaagggt	agcggagcca	tcagtgtct	tctcgaactg	catgtaccac	atgaaactat	16560
ctattacaat	acgctctttt	caaatagagt	gaaccccccg	caacgacatt	tcgggccgac	16620
cccaactcag	tttttgaatt	cgggtgttta	taggaatcta	caggcggagg	taacatgcaa	16680
agatggattt	gtccaagagt	tccgtccatt	atggagagaa	aatacagagg	aaagtgacct	16740
gacctcagat	aaagtagtgg	ggtatattac	atctgcagtg	ccctacagat	ctgtatcatt	16800
gctgcattgt	gacattgaaa	ttcctccagg	gtccaatcaa	agcttactag	atcaactagc	16860
tatcaattta	tctctgattg	ccatgcattc	tgttaagggtg	ggcggggtg	taatcatcaa	16920
agtgttgtat	gcaatgggat	actactttca	tctactcatg	aacttgtttg	ctccgtgttc	16980
cacaaaagga	tatatctct	ctaattggtta	tgcagtctga	ggagatatgg	agtgttacct	17040
ggtatttgtc	atgggttacc	tgggcggggc	tacatttgtta	catgagggtg	tgaggatggc	17100
gaaaactctg	gtgcagcggc	acggtacgct	tttgtctaaa	tcagatgaga	tcacactgac	17160
caggttattc	acctcacagc	ggcagcgtgt	gacagacatc	ctatccagtc	ctttaccaag	17220
attaataaaag	tacttgagga	agaatattga	cactgcgctg	attgaagccg	ggggacagcc	17280
cgtccgtcca	ttctgtgcgg	agagtctgggt	gagcacgcta	gcgaacataa	ctcagataac	17340
ccagatcatc	gctagtcaca	ttgacacagt	tatccggtct	gtgatataata	tgggaagctga	17400
gggtgatctc	gctgacacag	tatttctatt	taccccttac	aatctctcta	ctgacgggaa	17460
aaagaggaca	tcacttaaac	agtgcacgag	acagatccta	gaggttacaa	tactaggtct	17520
tagagtcgaa	aatctcaata	aaataggcga	tataatcagc	ctagtgttta	aaggcatgat	17580
ctccatggag	gaccttatcc	cactaaggac	atacttgaag	catagtacct	gccctaaata	17640
tttgaaggct	gtcctaggtta	ttaccaaact	caaagaaatg	tttacagaca	cttctgtact	17700

gtacttgact	cgtagctcaac	aaaaattcta	catgaaaact	ataggcaatg	cagtcaaagg	17760
atattacagt	aactgtgact	cttaacgaaa	atcacatatt	aataggctcc	ttttttggcc	17820
aattgtattc	ttgttgattt	aatcatatta	tgtagaaaa	aagttgaacc	ctgactcctt	17880
aggactcgaa	ttcgaactca	aataaatgtc	ttaaaaaaag	gttgcgacac	attattcttg	17940
agtgtagtct	cgtagctcac	caaattcttt	tttggttttg	tggccggcat	gggtccagcc	18000
tcctcgctgg	cgccggctgg	gcaacattcc	gaggggaccg	tcccctcggg	aatggcgaat	18060
gggacgcggc	cgatccggct	gctaacaaa	cccgaaggga	agctgagttg	gctgctgcca	18120
ccgctgagca	ataactagca	taaccccttg	gggcctctaa	acgggtcttg	aggggttttt	18180
tgctgaaagg	aggaactata	tccggatcgg	ccgatccggc	tgctaacaaa	gcccgaagg	18240
aagctgagtt	ggctgctgcc	accgctgagc	aataactagc	ataacccctt	ggggcctcta	18300
aacgggtctt	gaggggtttt	ttgctgaaag	gaggaactat	atccggatgg	ccgccaccgg	18360
tgggccttgc	agcacatccc	cccttcgcca	g			18391

<210> 2

<211> 1236

<212> DNA

<213> Homo sapiens

<400> 2

atggaacaac	ggggacagaa	cgccccggcc	gcttcggggg	cccggaaaag	gcacggccca	60
ggaccagggg	aggcgcgggg	agccaggcct	gggctccggg	tccccaagac	ccttggtgctc	120
gttgctgccg	cggtcctgct	gttggtctca	gctgagctctg	ctctgatcac	ccaacaagac	180
ctagctcccc	agcagagagc	ggccccacaa	caaaagaggt	ccagcccctc	agagggattg	240
tgtccacctg	gacaccatat	ctcagaagac	ggtagagatt	gcattctcctg	caaatatgga	300
caggactata	gcactcactg	gaatgacctc	cttttctgct	tgcgctgcac	caggtgtgat	360
tcaggtgaag	tggagctaag	tccctgcacc	acgaccagaa	acacagtgtg	tcagtgcgaa	420
gaaggcacct	tccgggaaga	agattctcct	gagatgtgcc	ggaagtgccg	cacagggtgt	480
cccagaggga	tggtaaggt	cgggtgattgt	acaccctgga	gtgacatcga	atgtgtccac	540
aaagaatcag	gcattcatcat	aggagtcaca	gttgacagccg	tagtcttgat	tgtggctgtg	600
tttgtttgca	agtctttact	gtggaagaaa	gtccttcctt	acctgaaagg	catctgctca	660
ggtggtggtg	gggacctga	gcgtgtggac	agaagctcac	aacgacctgg	ggctgaggac	720
aatgtcctca	atgagatcgt	gagtatcttg	cagcccaccc	aggtccctga	gcaggaaatg	780
gaagtccagg	agccagcaga	gccaacaggt	gtcaacatgt	tgtcccccg	ggagtcagag	840
catctgctgg	aaccggcaga	agctgaaagg	tctcagagga	ggaggctgct	ggttccagca	900
aatgaagggtg	atcccactga	gactctgaga	cagtgccttcg	atgactttgc	agacttggtg	960
ccctttgact	cctgggagcc	gctcatgagg	aagttgggcc	tcattggaca	tgagataaag	1020
gtggctaaa	ctgaggcagc	gggccacagg	gacaccttgt	acacgatgct	gataaagtgg	1080
gtcaacaaaa	ccgggcgaga	tgctctgttc	cacacctgtc	tggatgcctt	ggagacgctg	1140
ggagagagac	ttgccaagca	gaagattgag	gaccacttgt	tgagctctgg	aaagttcatg	1200
tatctagaag	gtaatgcaga	ctctgccatg	tcctaa			1236

<210> 3

<211> 624

<212> DNA

<213> Homo sapiens

<400> 3

atggagacag	acacactcct	gctatgggta	ctgctgctct	gggttccagg	atccactggt	60
acctctgagg	aaaccatttc	tacagttcaa	gaaaagcaac	aaaatatttc	tcccctagtg	120
agagaaaagag	gtcctcagag	agtagcagct	cacataactg	ggaccagagg	aagaagcaac	180
acattgtctt	ctccaaactc	caagaatgaa	aaggctcttg	gccgcaaaat	aaactcctgg	240
gaatcatcaa	ggagtgggca	ttcattcctg	agcaacttgc	acttgaggaa	tggtgaactg	300
gtcatccatg	aaaaagggtt	ttactacatc	tattcccaaa	catacttttcg	atttcaggag	360

gaaataaaaag	aaaacacaaa	gaacgacaaa	caaatggtcc	aatatatatta	caaatacaca	420
agttatcctg	accctatatt	gttgatgaaa	agtgctagaa	atagttgttg	gtctaaagat	480
gcagaatatg	gactctattc	catctatcaa	gggggaatat	ttgagcttaa	ggaaaatgac	540
agaattttttg	tttctgtaac	aatgagcac	ttgatagaca	tggaccatga	agccagtttt	600
ttcggggcct	ttttagttgg	ctaa				624

<210> 4
 <211> 462
 <212> DNA
 <213> Homo sapiens

<400> 4						
atgtacagga	tgcaactcct	gtcttgcat	gcactaagtc	ttgcacttgt	cacaaacagt	60
gcacctactt	caagttctac	aaagaaaaca	cagctacaac	tggagcattt	actgctggat	120
ttacagatga	ttttgaatgg	aattaataat	tacaagaatc	ccaaactcac	caggatgctc	180
acatttaagt	tttacatgcc	caagaaggcc	acagaactga	aacatcttca	gtgtctagaa	240
gaagaactca	aacctctgga	ggaagtgcta	aatttagctc	aaagcaaaaa	ctttcactta	300
agacccaggg	acttaatcag	caatatcaac	gtaatagttc	tggaaactaaa	gggatctgaa	360
acaacattca	tgtgtgaata	tgctgatgag	acagcaacca	ttgtagaatt	tctgaacaga	420
tggattacct	tttgtcaaag	catcatctca	acactgactt	aa		462

<210> 5
 <211> 1182
 <212> DNA
 <213> Homo sapiens

<400> 5						
atggaggagc	cgcagtcaga	tcctagcgtc	gagccccctc	tgagtcagga	aacattttca	60
gacctatgga	aactacttcc	tgaaaacaac	gttctgtccc	ccttgccgtc	ccaagcaatg	120
gatgatttga	tgctgtcccc	ggacgatatt	gaacaatggt	tcactgaaga	cccaggtcca	180
gatgaagctc	ccagaatgcc	agaggctgct	ccccccgtgg	cccctgcacc	agcagctcct	240
acaccggcgg	cccctgcacc	agccccctcc	tggccccgtg	catcttctgt	cccttcccag	300
aaaacctacc	agggcagcta	cggtttccgt	ctgggcttct	tgcatctctg	gacagccaag	360
tctgtgactt	gcacgtactc	ccctgccctc	aacaagatgt	tttgccaact	ggccaagacc	420
tgccctgtgc	agctgtgggt	tgattccaca	ccccgcgccg	gcacccgcgt	ccgcgccatg	480
gccatctaca	agcagtcaca	gcacatgacg	gaggttgtga	ggcgtgccc	ccaccatgag	540
cgctgctcag	atagcgatgg	tctggccccct	cctcagcatc	ttatccgagt	ggaaggaaat	600
ttgcgtgtgg	agtatttgga	tgacagaaac	acttttcgac	atagtgtggt	ggtgccctat	660
gagccgcctg	aggttggctc	tgactgtacc	accatccact	acaactacat	gtgtaacagt	720
tcttgcattg	gcggcatgaa	ccggaggccc	atcctcacca	tcacacact	ggaagactcc	780
agtggtaatc	tactgggacg	gaacagcttt	gaggtgcgtg	tttgtgcctg	tcctgggaga	840
gaccggcgca	cagaggaaga	gaatctccgc	aagaaagggg	agcctcacca	cgagctgccc	900
ccaggagagca	ctaagcgagc	actgcccac	aacaccagct	cctctcccca	gccaaagaag	960
aaaccactgg	atggagaata	tttcaccctt	cagatccgtg	ggcgtgagcg	cttcgagatg	1020
ttccgagagc	tgaatgaggc	cttggaactc	aaggatgccc	aggctgggaa	ggagccaggg	1080
gggagcaggg	ctcactccag	ccacctgaag	tccaaaaagg	gtcagtctac	ctcccgccat	1140
aaaaaactca	tgttcaagac	agaagggcct	gactcagact	ga		1182

<210> 6
 <211> 504
 <212> DNA
 <213> Homo sapiens

<400> 6
atggagacag acacactcct gctatgggta ctgctgctct gggttccagg atccactggt 60
ccaggatggg tcttagactc cccagacagg ccctggaacc cccccacctt ctccccagcc 120
ctgctcgtgg tgaccgaagg ggacaacgcc accttcacct gcagcttctc caacacatcg 180
gagagcttcg tgctaaactg gtaccgcatg agccccagca accagacgga caagctggcc 240
gccttccccg aggaccgcag ccagcccggc caggactgcc gcttccgtgt cacacaactg 300
cccaacgggc gtgacttcca catgagcgtg gtcagggccc ggcgcaatga cagcggcacc 360
tacctctgtg gggccatctc cctggccccc aaggcgcaga tcaaagagag cctgcgggca 420
gagctcaggg tgacagagag aagggcagaa gtgcccacag cccaccccag cccctcacc 480
aggccagccg gccagttcca atga 504

<210> 7
<211> 1284
<212> DNA
<213> Escherichia coli

<400> 7
atgtcgaata acgctttaca aacaattatt aacgcccggg taccaggcga agaggggctg 60
tggcagattc atctgcagga cggaaaaatc agcgccattg atgcgcaatc cggcgtgatg 120
cccataactg aaaacagcct ggatgccgaa caagggttag ttataccgcc gtttgtggag 180
ccacatattc acctggacac cacgcaaacc gccggacaac cgaactggaa tcagtccggc 240
acgctgtttg aaggcattga acgctgggcc gagcgcaaag cgttattaac ccatgacgat 300
gtgaaacaac gcgcatggca aacgctgaaa tggcagattg ccaacggcat tcagcatgtg 360
cgtacccatg tcgatgtttc ggatgcaacg ctaactgcgc tgaaagcaat gctggaagtg 420
aagcaggaag tcgcccgtg gattgatctg caaatcgtcg ccttccctca ggaagggatt 480
ttgtcgtatc ccaacggtga agcgttgctg gaagaggcgt tacgcttagg ggcagatgta 540
gtggggggcga ttccgcattt tgaatttacc cgtgaatacg gcgtggagtc gctgcataaa 600
accttcgccc tggcgcaaaa atacgaccgt ctcatcgacg ttactgtga tgagatcgat 660
gacgagcagt cgcgctttgt cgaaaccgtt gctgccctgg cgcaccatga aggcattggc 720
gcgcgagtca ccgccagcca caccacggca atgcactcct ataacggggc gtatacctca 780
cgcctgttcc gcttgctgaa aatgtccggg attaaacttg tcgccaaccc gctggtcaat 840
attcatctgc aaggacgttt cgatacgtat ccaaaacgtc gcggcatcac gcgcgttaaa 900
gagatgctgg agtccggcat taacgtctgc tttggtcacg atgatgtctt cgatccgtgg 960
tatccgctgg gaacggcgaa tatgctgcaa gtgctgcata tggggctgca tgtttgccag 1020
ttgatgggct acgggcagat taacgatggc ctgaatttaa tcaccacca cagcgaagg 1080
acgttgaatt tgcaggatta cggcattgcc gccggaaaca gcgccaacct gattatcctg 1140
ccggctgaaa atgggtttga tgcgctgcgc cgtcaggttc cggtagctta ttcggtacgt 1200
ggcggcaagg tgattgccag cacacaaccg gcacaaacca ccgtatatct ggagcagcca 1260
gaagccatcg attacaaacg ttga 1284

<210> 8
<211> 1623
<212> DNA
<213> Mus musculus

<400> 8
atgtgtcaat cacgctacct cctctttttg gccacccttg ccctcctaaa ccacctcagt 60
ttggccaggg tcattccagt ctctggacct gccagggtgtc ttagccagtc ccgaaacctg 120
ctgaagacca cagatgacat ggtgaagacg gccagagaaa agctgaaaca ttattcctgc 180
actgtgaag acatcgatca tgaagacatc acacgggacc aaaccagcac attgaagacc 240
tgtttaccac tggaactaca caagaacgag agttgcctgg ctactagaga gacttcttcc 300
acaacaagag ggagctgcct gccccacag aagacgtctt tgatgatgac cctgtgcctt 360
ggtagcatct atgaggactt gaagatgtac cagacagagt tccaggccat caacgcagca 420

cttcagaatc	acaacccatca	gcagatcatt	ctagacaagg	gcatgctggt	ggccatcgat	480
gagctgatgc	agtctctgaa	tcataatggc	gagactctgc	gccagaaacc	tcctgtggga	540
gaagcagacc	cttacagagt	gaaaatgaag	ctctgcatcc	tgcttcacgc	cttcagcacc	600
cgcgtcgtga	ccatcaacag	ggtgatgggc	tatctgagct	ccgccgttcc	tggagtaggg	660
gtacctggag	tgggcggatc	tatgtgggag	ctggagaaag	acgtttatgt	tgtagagggtg	720
gactggactc	ccgatgcccc	tggagaaaca	gtgaacctca	cctgtgacac	gcctgaagaa	780
gatgacatca	cctggacctc	agaccagaga	catggagtca	taggctctgg	aaagaccctg	840
accatcactg	tcaaagagtt	tctagatgct	ggccagtaca	cctgccacaa	aggaggcgag	900
actctgagcc	actcacatct	gctgctccac	aagaaggaaa	atggaatttg	gtccactgaa	960
attttaaaaa	atttcaaaaa	caagactttc	ctgaagtgtg	aagcaccaaa	ttactccgga	1020
cggttcacgt	gctcatggct	ggtgcaaaga	aacatggact	tgaagttcaa	catcaagagc	1080
agtagcagtc	ccccgactc	tcgggcagtg	acatgtggaa	tggcgtctct	gtctgcagag	1140
aaggtcacac	tggaccaaag	ggactatgag	aagtattcag	tgtcctgcca	ggaggatgtc	1200
acctgcccc	ctgccgagga	gaccctgccc	attgaactgg	cgttggaagc	acggcagcag	1260
aataaatatg	agaactacag	caccagcttc	ttcatcaggg	acatcatcaa	accagaccgc	1320
cccaagaact	tgcagatgaa	gcctttgaag	aactcacagg	tggaggtcag	ctgggagtag	1380
cctgactcct	ggagcactcc	ccattcctac	ttctccctca	agttctttgt	tcgaatccag	1440
cgcaagaaag	aaaagatgaa	ggagacagag	gaggggtgta	accagaaagg	tgcgttcctc	1500
gtagagaaga	catctaccga	agtccaatgc	aaaggcgga	atgtctgcgt	gcaagctcag	1560
gatcgctatt	acaattcctc	atgcagcaag	tgggcatgtg	ttccctgcag	ggtccgatcc	1620
tag						1623

What is claimed is:

1. A recombinant Newcastle disease virus, being obtained by replacing an F protein of a Newcastle disease virus Losata with an F protein of a Newcastle disease virus virulent strain.

2. The recombinant Newcastle disease virus according to claim 1, wherein a coding DNA of an F protein of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1 at positions 7274-8935 from a 5'-terminus.

3. The recombinant Newcastle disease virus according to claim 1, wherein the recombinant Newcastle disease virus is obtained by replacing an F gene in a genome of the Newcastle disease virus Losata with an F gene of the Newcastle disease virus virulent strain, wherein

preferably, a DNA corresponding to the F gene of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1 at the positions 7274-8935 from the 5'-terminus; and

more preferably, a DNA corresponding to a genome of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1.

4. The recombinant Newcastle disease virus according to claim 1, wherein a DNA corresponding to a genome of the recombinant Newcastle disease virus further comprises an exogenous gene, which is selected from one or more of a group consisting of DR5, TRAIL, hIL2, P53, PD1, CD, and mIL12;

preferably, the exogenous gene is DR5, TRAIL, hIL2, P53, PD1, CD, or mIL12;

preferably, the exogenous gene is mIL12-hIL2, P53-hIL2, PD1-hIL2, or DR5-TRAIL;

preferably, the DR5 is as set forth in SEQ ID NO: 2, the TRAIL is as set forth in SEQ ID NO: 3, the hIL2 is as set forth in SEQ ID NO: 4, the P53 is as set forth in

SEQ ID NO: 5, the PD1 is as set forth in SEQ ID NO: 6, the CD is as set forth in SEQ ID NO: 7, and the mIL12 is as set forth in SEQ ID NO: 8; and

preferably, the exogenous gene is located between a P gene and an M gene of the recombinant Newcastle disease virus.

5

5. A recombinant plasmid obtained by replacing an F gene in a pBrLosata plasmid, wherein the F gene of the recombinant plasmid is as set forth in SEQ ID NO: 1 at positions 7274-8935 from a 5'-terminus.

10

6. The recombinant plasmid according to claim 5, wherein the recombinant plasmid is a DNA molecule plasmid as set forth in SEQ ID NO: 1.

15

7. The recombinant plasmid according to claim 5, further comprising an exogenous gene, which is selected from one or more of a group consisting of DR5, TRAIL, hIL2, P53, PD1, CD, and mIL12, wherein

preferably, the exogenous gene is DR5, TRAIL, hIL2, P53, PD1, CD, or mIL12;

preferably, the exogenous gene is mIL12-hIL2, P53-hIL2, PD1-hIL2, or DR5-TRAIL;

20

preferably, the DR5 is as set forth in SEQ ID NO: 2, the TRAIL is as set forth in SEQ ID NO: 3, the hIL2 is as set forth in SEQ ID NO: 4, the P53 is as set forth in SEQ ID NO: 5, the PD1 is as set forth in SEQ ID NO: 6, the CD is as set forth in SEQ ID NO: 7, and the mIL12 is as set forth in SEQ ID NO: 8; and

25

preferably, the exogenous gene is located between a P gene and an M gene of a genome of the recombinant Newcastle disease virus.

8. A preparation method for a recombinant Newcastle disease virus, comprising transfecting the recombinant plasmid according to any one of claims 5 to 7 to a cell or cell line for culturing to obtain the recombinant Newcastle disease virus.

30

9. The preparation method according to claim 8, wherein
the recombinant plasmid according to any one of claims 5 to 7 and a helper
plasmid are co-transfected to a cell or cell line for culturing; and
the cell is a mammalian cell.

5

10. Use of the recombinant Newcastle disease virus according to any one of
claims 1 to 4 or the recombinant plasmid according to any one of claims 5 to 7 in
preparation of a drug having the following function(s) of (a) and/or (b) and/or (c):

- (a) treating a tumour;
- (b) inhibiting tumour cell proliferation; and
- (c) killing tumour cells.

10

11. The use according to claim 10, wherein

the tumour is selected from one or more of a group consisting of a liver
cancer, a breast cancer, a non-small cell lung cancer, a melanoma, a neuroblastoma, a
lung cancer, a pancreatic cancer, a thyroid cancer, a kidney cancer, a glioma, a
myosarcoma, an esophageal cancer, a uterine cancer, a breast cancer, and a colon
cancer; and

15

the tumour cell is selected from one or more of a group consisting of a liver
cancer cell, a breast cancer cell, a non-small cell lung cancer cell, a melanoma cell, a
neuroblastoma cell, a lung cancer cell, a pancreatic cancer cell, a thyroid cancer cell, a
kidney cancer cell, a glioma cell, a myosarcoma cell, an esophageal cancer cell, a
uterine cancer cell, a breast cancer cell, and a colon cancer cell.

20

12. A drug, comprising

the recombinant Newcastle disease virus according to any one of claims 1 to
4, and/or

the recombinant plasmid according to any one of claims 5 to 7, wherein
the drug has the following function(s) of (a) and/or (b) and/or (c):

- (a) treating a tumour;

30

- (b) inhibiting tumour cell proliferation; and
- (c) killing tumour cells.